var title_f5_28_5568="Contents: Pediatric gastroenterology";
var content_f5_28_5568=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric gastroenterology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric gastroenterology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Abdominal pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/20/11593\">",
"           Causes of acute abdominal pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/61/22490\">",
"           Emergent evaluation of the child with acute abdominal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/17/1306\">",
"           Evaluation of the child and adolescent with chronic abdominal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/52/6984\">",
"           Management of the child and adolescent with chronic abdominal pain",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Celiac disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/3/37946\">",
"           Clinical manifestations and diagnosis of celiac disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/47/7929\">",
"           Management of celiac disease in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Constipation and encopresis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/63/15354\">",
"           Constipation in children: Etiology and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/9/44182\">",
"           Definition, clinical manifestations, and evaluation of functional fecal incontinence in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/41/2710\">",
"           Prevention and treatment of acute constipation in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/28/36298\">",
"           Treatment of chronic functional constipation and fecal incontinence in infants and children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cystic fibrosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29095\">",
"           Cystic fibrosis: Assessment and management of pancreatic insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/24/15754\">",
"           Cystic fibrosis: Nutritional issues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/15/19706\">",
"           Cystic fibrosis: Overview of gastrointestinal disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Developmental abnormalities of the GI tract",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/29/3545\">",
"           Infantile hypertrophic pyloric stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/55/31608\">",
"           Intestinal atresia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/48/20232\">",
"           Intestinal malrotation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diarrhea and gastroenteritis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/43/35511\">",
"           Approach to the diagnosis of chronic diarrhea in children in developed countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/40/38535\">",
"           Clinical manifestations and diagnosis of Shigella infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/1/42008\">",
"           Epidemiology, microbiology, and pathogenesis of Shigella infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/56/14216\">",
"           Epidemiology, pathogenesis, clinical presentation and diagnosis of viral gastroenteritis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/13/13529\">",
"           Evaluation of diarrhea in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/2/16426\">",
"           Food poisoning in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/52/34631\">",
"           Food protein-induced proctitis/colitis and enteropathy of infancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/60/5065\">",
"           Microbiology, pathogenesis, and epidemiology of Campylobacter infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/5/5210\">",
"           Overview of the causes of chronic diarrhea in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/53/15188\">",
"           Pathogenesis of acute diarrhea in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/1/27\">",
"           Patient information: Acute diarrhea in children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/37/43609\">",
"           Persistent diarrhea in children in developing countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/43/9912\">",
"           Prevention and treatment of viral gastroenteritis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/62/40937\">",
"           Rotavirus vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/59/30649\">",
"           Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         ERCP",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/3/20536\">",
"           ERCP for biliary disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/33/24088\">",
"           ERCP for pancreatic disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/45/4822\">",
"           ERCP in children: Technique, success and complications",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Esophageal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/23/4473\">",
"           Caustic esophageal injury in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/41/41625\">",
"           Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/22/1386\">",
"           Foreign bodies of the esophagus and gastrointestinal tract in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/46/30441\">",
"           Gastroesophageal reflux in infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/6/23657\">",
"           Gastroesophageal reflux in premature infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/33/19994\">",
"           Management of gastroesophageal reflux disease in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/45/32474\">",
"           Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Food allergy and intolerance",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/52/34631\">",
"           Food protein-induced proctitis/colitis and enteropathy of infancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/32/5641\">",
"           Lactose intolerance",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal bleeding",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/0/1033\">",
"           Approach to upper gastrointestinal bleeding in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/52/29513\">",
"           Diagnostic approach to lower gastrointestinal bleeding in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/52/34631\">",
"           Food protein-induced proctitis/colitis and enteropathy of infancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/59/30649\">",
"           Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal hormones",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/33/16917\">",
"           Overview of gastrointestinal peptides in health and disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/8/22660\">",
"           Synthesis, secretion, and regulation of gastrointestinal peptides",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hirschsprung disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/55/41848\">",
"           Congenital aganglionic megacolon (Hirschsprung disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/8/34950\">",
"           Emergency complications of Hirschsprung disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Inflammatory bowel disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/25/27034\">",
"           Clinical features and diagnosis of inflammatory bowel disease in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/7/24693\">",
"           Clinical manifestations of Crohn's disease in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/13/3288\">",
"           Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/26/44455\">",
"           Genetic factors in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/46/2794\">",
"           Growth failure and poor weight gain in children with inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/6/43113\">",
"           Nutrient deficiencies in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/47/41722\">",
"           Overview of the management of Crohn's disease in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/34/4650\">",
"           Treatment of ulcerative colitis in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nausea and vomiting",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/60/24521\">",
"           Approach to the infant or child with nausea and vomiting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/48/34568\">",
"           Cyclic vomiting syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neonatal conditions",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/39/41591\">",
"           Clinical features and diagnosis of necrotizing enterocolitis in newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/5/35928\">",
"           Management of necrotizing enterocolitis in newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/59/37816\">",
"           Neonatal hyperglycemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/28/28105\">",
"           Pathology and pathogenesis of necrotizing enterocolitis in newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/2/7207\">",
"           Prevention of necrotizing enterocolitis in newborns",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Normal development of the GI tract",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/15/41205\">",
"           Overview of the development of the gastrointestinal tract",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutrition",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/8/19593\">",
"           Approach to enteral nutrition in the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/45/29400\">",
"           Chronic complications of the short bowel syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/12/14538\">",
"           Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/6/23655\">",
"           Human milk feeding and fortification of human milk for premature infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/31/32248\">",
"           Malnutrition in developing countries: Clinical assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/9/26778\">",
"           Management of the short bowel syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/28/458\">",
"           Nutritional composition of human milk and preterm formula for the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/56/30601\">",
"           Pathophysiology of the short bowel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/61/9178\">",
"           Severe malnutrition in children in developing countries: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Obesity",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/11/8378\">",
"           Clinical evaluation of the obese child and adolescent",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/8/134\">",
"           Clinical features, diagnosis, and treatment of Prader-Willi syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/50/37674\">",
"           Comorbidities and complications of obesity in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/5/32858\">",
"           Definition; epidemiology; and etiology of obesity in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/8/16516\">",
"           Epidemiology and genetics of Prader-Willi syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/60/18378\">",
"           Management of childhood obesity in the primary care setting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/47/16122\">",
"           Surgical management of severe obesity in adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pancreatic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/55/18293\">",
"           Annular pancreas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/46/42727\">",
"           Causes of chronic pancreatitis in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/5/20569\">",
"           Clinical manifestations and diagnosis of acute pancreatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/60/28616\">",
"           Clinical manifestations and diagnosis of chronic pancreatitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/61/14297\">",
"           Etiology of acute pancreatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/26/37288\">",
"           Hereditary pancreatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/46/44774\">",
"           Pathogenesis of acute pancreatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/29/44504\">",
"           Predicting the severity of acute pancreatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/39/33400\">",
"           Shwachman-Diamond syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/35/7738\">",
"           Treatment of acute pancreatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/40/31369\">",
"           Treatment of chronic pancreatitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Small intestine and colon",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/3/37946\">",
"           Clinical manifestations and diagnosis of celiac disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/2/14377\">",
"           Diagnosis of celiac disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/20/35145\">",
"           Intussusception in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/47/7929\">",
"           Management of celiac disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/3/21561\">",
"           Overview of inguinal hernia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/48/32519\">",
"           Overview of rectal prolapse in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/62/33768\">",
"           Overview of blunt abdominal trauma in children",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-FD9C19337B-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f5_28_5568=[""].join("\n");
var outline_f5_28_5568=null;
var title_f5_28_5569="Gliquidone: International drug information";
var content_f5_28_5569=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gliquidone: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1978937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Glurenor (DE, ES, IT, PT);",
"     </li>",
"     <li>",
"      Glurenorm (AT, BE, CZ, DE, GB, HR, HU, LU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiabetic Agent, Sulfonylurea",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 2 (noninsulin-dependent) diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Initial: 15 mg daily before breakfast; range: 45-60 mg daily in 2-3 divided doses; maximum single dose: 60 mg; maximum daily dose: 180 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 30 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10389 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-210.101.131.231-DF96EE1385-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_28_5569=[""].join("\n");
var outline_f5_28_5569=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978937\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978932\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978935\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978931\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821172\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978934\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10389\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10389|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_28_5570="Lung cancer prevention and screening";
var content_f5_28_5570=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Lung cancer prevention and screening (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/28/5570/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/28/5570/contributors\" id=\"au969\">",
"       Mark E Deffebach, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/28/5570/contributors\" id=\"au918\">",
"       Linda Humphrey, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/28/5570/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/28/5570/contributors\" id=\"se4114\">",
"       James R Jett, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/28/5570/contributors\" id=\"se323\">",
"       Robert H Fletcher, MD, MSc",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/28/5570/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/28/5570/contributors\" id=\"de162\">",
"       H Nancy Sokol, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?5/28/5570?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      LUNG CANCER SCREENING OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Lung cancer is the leading cause of cancer death in both men and women in the United States. The number of people who die from lung cancer each year has risen over the past 25 years. The number of people who die from lung cancer is greater than the number of people who die from breast cancer, prostate cancer, and colorectal cancer combined. Several factors increase the risk of lung cancer, particularly cigarette smoking.",
"    </p>",
"    <p>",
"     This topic review discusses ways to prevent lung cancer and discusses the benefits and risks of screening for lung cancer. Other topics about lung cancer are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=see_link\">",
"      \"Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/22/41314?source=see_link\">",
"      \"Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/63/17396?source=see_link\">",
"      \"Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/8/22659?source=see_link\">",
"      \"Patient information: Small cell lung cancer treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PREVENTING LUNG CANCER",
"     </span>",
"    </p>",
"    <p>",
"     Cigarette smoking is responsible for almost 90 percent of cases of lung cancer. Exposure to certain substances, such as asbestos, has also been linked to the development of lung cancer. Exposure to secondhand smoke and other environmental factors such as radon and asbestos also increase the risk of lung cancer.",
"    </p>",
"    <p>",
"     The best way to avoid getting lung cancer is not to smoke. Some smokers believe that once they have smoked for a long while, it does little good to quit. However, studies have shown that smokers who quit decrease their risk of lung cancer when compared to those who continue to smoke. Smokers who quit for more than 15 years have an 80 to 90 percent reduction in their risk of lung cancer compared to people who continue to smoke. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      \"Patient information: Quitting smoking (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      IS SCREENING WORTHWHILE?",
"     </span>",
"    </p>",
"    <p>",
"     Screening is a way to detect a disease in its earliest stages, before a person becomes ill. To be recommended, it must be clear that screening is useful in identifying patients who have the disease in the early stages, and that this discovery can reduce the number of patients who die from the disease.",
"    </p>",
"    <p>",
"     Some screening exams have proven to make a clear difference in outcomes. Examples are the Pap smear for detection of cervical cancer in women, and colonoscopy for detection of colon or rectal cancer in people over 50 years old. These exams are now part of routine healthcare in the United States.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      LUNG CANCER SCREENING EXAMS",
"     </span>",
"    </p>",
"    <p>",
"     Research studies have been done to determine if screening for lung cancer makes sense. In these studies, smokers (who are at the highest risk) are divided into groups. Some groups have screening tests while others have no screening. The groups are then followed over many years. Data are gathered on how many patients in each group are diagnosed with lung cancer, how the cancer was treated, how long the patients with lung cancer survived after treatment, and how many patients died from the disease (mortality).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Chest x-ray",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although many healthcare providers recommend an annual chest x-ray for patients who smoke, studies to date have not shown a clear benefit. In patients who had more frequent chest x-rays, more lung cancers were found at early stages, the cancers were more frequently removable by surgery, and the patients had longer five-year survival (from time of diagnosis) than patients with less frequent x-rays. However, the same number of advanced cancers were found in each group and the death rates for lung cancer were not different. &nbsp;A concern is that since overall death from lung cancer was not significantly different, these findings may represent overdiagnosis (finding cancer that would not affect health during a person&rsquo;s lifetime). Chest x-ray is not recommended for lung cancer screening.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Computed tomography (CT scan)",
"     </span>",
"     &nbsp;&mdash;&nbsp;A large randomized trial in the United States compared the benefits of screening by low-dose CT scan or chest x-ray in smokers (at least a 30 pack-year history, including current smokers or people who had quit in the previous 15 years). Compared to chest x-ray, low-dose CT scan reduced the risk of death from lung cancer by 20 percent, and the overall risk of death by about 7 percent. However, nearly a quarter of the patients who had annual CT screening for three years had an abnormal test, and more than 95 percent of the abnormal tests were &ldquo;false positive&rdquo; meaning that they did not represent cancer. False positive tests require follow-up tests, such as more x-rays or biopsies, and these follow-up tests carry risks such as increasing radiation exposure, and complications from biopsy procedures. Thus, there are significant downsides to screening. Additionally, screening may be costly and it is unclear whether insurance companies will pay for it.",
"    </p>",
"    <p>",
"     The results of this trial are encouraging, but it is not certain if the decrease in mortality would also occur with CT screening outside of the research setting. The patients enrolled in the trial were healthier than the average smoker in the United States, and the doctors involved in the trial might be better than other doctors at reading low-dose CT scans and investigating abnormal findings. Patients with increased risk for lung cancer (similar to or greater than the risk of the participants in the trial) should discuss the risks and benefits of low-dose CT screening with their doctors, and recognize that the most important way to prevent lung cancer is to stop smoking. Patients who choose screening should have a yearly scan, and make sure that follow-up of any abnormal finding is done by doctors who are expert in diagnosing lung cancer.",
"    </p>",
"    <p>",
"     Other large randomized controlled trials of screening with low-dose CT chest screening are underway and the results are anticipated in the next few years.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Sputum tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some studies have looked at the efficacy of analyzing a patient's sputum for evidence of cancer cells in order to detect lung cancer. So far, no clear benefit to this approach has been found. Additional studies that use new technologies to examine the sputum are underway.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      PET scan",
"     </span>",
"     &nbsp;&mdash;&nbsp;Researchers are looking at a number of other tools in an effort to help identify patients with lung cancer. Positron Emission Tomography (or PET scanning, which uses a small amount of radioactivity to provide a detailed picture of an organ's function) has been used in combination with CT scanning",
"     <span class=\"nowrap\">",
"      (PET/CT).",
"     </span>",
"     However it involves a higher dose of radiation than CT alone and benefit has not been shown for screening purposes.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Other studies",
"     </span>",
"     &nbsp;&mdash;&nbsp;Direct visualization of the lungs with bronchoscopy and breath analysis for cancer markers are two tests that may be used in future studies.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Patients who smoke are at significantly increased risk of developing lung cancer. The best way to avoid lung cancer is not to smoke. Even long-term smokers can benefit from quitting.",
"      </li>",
"      <li>",
"       Researchers are looking for ways to help smokers and non-smokers who develop lung cancer live longer. Early detection and screening is a major focus of this effort.",
"      </li>",
"      <li>",
"       Screening with yearly low dose CT scan decreased mortality in a randomized trial of patients with increased risk due to smoking. However, many patients had abnormal tests that did not turn out to be lung cancer. Whether or not to be screened should be based on a discussion of risks and benefits with a healthcare provider, and include evaluation of the patient&rsquo;s risk, the costs involved in screening, and the expertise of the center where the screening would be done.",
"      </li>",
"      <li>",
"       Screening with chest x-rays is not recommended.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784812983\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20924133\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/13/11475?source=see_link\">",
"      Patient information: Lung cancer screening (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=see_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/44/3779?source=see_link\">",
"      Patient information: Non-small cell lung cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/34/35363?source=see_link\">",
"      Patient information: Lung cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/38/24162?source=see_link\">",
"      Patient information: Small cell lung cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20924198\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=see_link\">",
"      Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/22/41314?source=see_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/63/17396?source=see_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/8/22659?source=see_link\">",
"      Patient information: Small cell lung cancer treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42378?source=see_link\">",
"      Cancer prevention",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8902?source=see_link\">",
"      Chemoprevention of lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21511?source=see_link\">",
"      Fluorescence bronchoscopy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28586?source=see_link\">",
"      Screening for lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=see_link\">",
"      Secondhand smoke exposure: Effects in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10072?source=see_link\">",
"      Women and lung cancer",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancernet.nci.nih.gov/\">",
"      www.cancernet.nci.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Lung Cancer Alliance",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lungcanceralliance.org/\">",
"      www.lungcanceralliance.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?5/28/5570/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 18, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?5/28/5570?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5570/abstract/1\">",
"      Truong MT, Munden RF. Lung cancer screening. Curr Oncol Rep 2003; 5:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5570/abstract/2\">",
"      Nawa T, Nakagawa T, Kusano S, et al. Lung cancer screening using low-dose spiral CT: results of baseline and 1-year follow-up studies. Chest 2002; 122:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5570/abstract/3\">",
"      Bastarrika G, Garc&iacute;a-Velloso MJ, Lozano MD, et al. Early lung cancer detection using spiral computed tomography and positron emission tomography. Am J Respir Crit Care Med 2005; 171:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5570/abstract/4\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f5_28_5570=[""].join("\n");
var outline_f5_28_5570=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           LUNG CANCER SCREENING OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           PREVENTING LUNG CANCER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           IS SCREENING WORTHWHILE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           LUNG CANCER SCREENING EXAMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f5_28_5571="Child insulin injection sites PI";
var content_f5_28_5571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F57381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F57381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Where to give your child an insulin shot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 559px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The shaded areas of the body (as shown above) can be used for insulin shots. You should change areas so that you don't give your child an insulin shot in the same part of the body each time. In children who are school-age and older, you can also give an insulin shot in the belly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_28_5571=[""].join("\n");
var outline_f5_28_5571=null;
var title_f5_28_5572="Verrucous carcinoma aka Giant condyloma of Buschke-Lowenstein";
var content_f5_28_5572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Verrucous carcinoma (also known as Giant condyloma of Buschke-Lowenstein)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwC5PIsVxleZiAAD2O0c07aRAiqDl+W56gf4nmhbd2v5pJfKWMBc5fJAwAF46Zx1pslxGZWzN838WxDjHtmsD6da2sQaQWQ3HmRkoh8sAdyTkZ/AUwmSXDgAO5/IVYmmhtkgt9rZl/fHJxkfdGaYZVjlfai7lx93nApbIcW97DSjxu5Zd746Doufen4dbOcF1XlT7jPb+VIwkmARpZDxli3f3NPMYt7JjIQxk3MvHUgDFG4SlpqZz5jtzJISSc5z3561U3s8uXVWzwF9KkuMyyATHpznPSoZXxMXQchcBT79qzbNERQsWbc3yjnGR0q8hUIuF4255qjagtKFYHAyTx0rSC7QsjDljkg+lNEyY2PYqoCuWfoM8Cq9wwMSOSSxcqAOgA6mpkDXMgG4qhBOegH/AOqq05VyzxnbGowCfT1x71qtjGWpBKDNcHCl5GwqJ/SqF6FB+zxncqZLsDwzdz9B0FacbmONpRwxUgE/wr3P17VjuCqsx4RjgetJ7GD3Mm5HlTMp+7gAH0NRv+70a6fjMjrGM+g5P9KsXg81CMc5yD9Kg1HC6daRjGW3vj6nr+lTEzkc7KcFmI5x39aksPliZ85I4A9zSXSEAHHBzg/SnaUPNnV5P9VGpkYdvaqSuYSlZmjdo0UUaZUtj5s9qsCEWul+ZMzATcKB6d6zIZTNPvcbtx3fU9hV7XJlN+NuXSFVQAdN2OcVVt2iU+hFD5SIHKlsdF6YFWkuCkfTGecegqvJEiostwfLYjhd1QIwYfOxA/vdahpo0TuWHuW89Ut2YtIQAPfNaLTLbl4JWYgIS0gGct/gKzolMcn7tk+0EfLk4Kj/ABNV7ya5iOySCWJBj74xuoV0hNq5fn24BZomyOAR2qot3GrhIYkyepPAFU95uWCTNgMeCoxtq08SRQ7SoYDoT1H41JabJxLtcqPmJHLE1mySiKYMhIXOME9R3FEsgWPdE5D9CD2qgX33AGPlTnPvRYfN0NVGCuVQEDqvuKc8rnuF+lQQymXAHVBge4qKZ2HWgaY0PmV1J+XtUiDC9OT0qqP3mXHSM8e5qeOYAhwwyelUkZtiXH7sHu+Mn2qFTmMNn5jUDXPmSHYM+5p0WdhyRuzTsRcc8m0bGHXmonlUqQw4NFw5EvXkDqaScLsyOmKpEtmVbMFlkQH5c1IcgmojHiTI6k808kFtvX3qzIJX3HjoKhJB+WnNxTEPXjmrQmNKZZR1FQ3JDOCo9qtKMBm9BiqjjB4qkZtDB71oWblBuJwv86pxjqzD5R29aeWJbcTz7VSdhWN+G5yBgYFSpMTISxzn1rMs2DR9easB9rrhhx2rRMho0iQgJbj3piAuc8hPcdabPMghAI470+Bi8YIqySyiI5JKrgetOtwpZkAOw8rmq8ffccjrSPI7TqEOFIwTQIt+ad2xPmYd6lXABzgk9TVWJwG2j8TVhiAvFMRIJAz4B5/lVhTlTVGHJJPerMbEnAoA9ov9qTzQRnKocuQerDr+XSqKbpZVj6hjjb/ept1JuupiAGbzT171NaYjje4kY/J0x1J7Afj/ACryL6n1lrRIxBNPqZkjiMrIhRVUbsAdT9Opqb7Dcq3yxj1YvhRntkn0pn2hjMo3YEUeAqcZJOST6mmD55V75G7JH86NGF2i4seJEiEsbO2ADHyDj3/nTLld8wkRzLCqtESR93g8fQ9felhkS2tXunbBYhUXb/nv/KqFjNIkuSzOGR96nptwTg/54qr9CeVu8jMuPmUglsbtxxxj8ajeVo9meXU9MdD61b8qGVZJNxjyMlGXcFH19qy5y0M7JIBuVs5/ven4dDWb01L5i7aNlHZgWZjgH0q8jM5CLkseBjrWXZMGJyxLYzx/StW1IVnIwSOH56D+6PeqiZyYy+QwxGBfnmcDzNpzhR0Ue3r61TkhA/dqxOAN5/ma0XWdpHeOGUygAgqnA9MnpTHsJ9zbmQbuXZnAyfp71dnczuZ9wyeUqRqdpI+uKyZlMrFRnYDwK2JYUIbfeRByefLRmwPY8VQvPITCpK+MdRHzj86JGTMy72jIT86y9YOZIQMDy41QD9f61pXUluV6z4I6AKKztVEX2osglJZVbBIxyKlGcjGvTtgBY4wCufrVaSZl01IbYfvbt9vH9wVPrex18hVfIIT5SMhmrOmJtb3y4mZiiiKMDse5/OtY7HLPc2bJo4mAjbcUYLntnufwpb6cR3knlKdofk+pPYUBVs4FaQZdVC/KO/X+dZt+8z6g4DBIk5LHvxzTasrEpk2x57lmkJx6E5wK0I0RF/cnLLwCeQPf61iwXrvIEgXG4hQDyWPqa2IXkaFVdVWJGwXPQ46n/CptYu9yrImSVZiWJ+Y4p8N9c2hZbeZtg4w3IP1BqK4n3SuEGyPI256tVW6fayfNhB2qGtS01YtS36yNm4iVHPeIYB/CpDM/2RnDBl6Kw9fcVkXJYoCWGOw9KfbSSz+XDCcbSQT/ADpqNyXK2gpuGKSljvxwcU+1MbRYDfKeqnrTZDC8hhinEWDncR8rt/SopI5IW8uROvOR3+lDQJmtFJCkIdXUnpjFUGnLz+UBkHoc9DVdrhU2gHMR4Yj19ag3PHqGxFYnII+lOwORZfehCqflXrj1qKFwsgGSOSTn0pLqceY4zgbudvWqYlU3JxuGE6mmkS5F63ZY4txOagMzh/kztao2fao2c8UiuWXB6+tOwrknzNKQWOTUksipH8xye1V2JSLJOTUG5pMM3OO5pktkjyF+BmmA4Py9KFbg8fjUTPtODxmmSxw3Hr0pu0huv5V13hjwv9vtY7y8ZhA2dsa8MwHfNdW3guxuLIpDZGPf0m7j15pcx0wwk5x5keVxRyTjy4UeRieiqSa2tM8G6tfXJSa3eyjAyZJ0I/IdTXsfh7QLaBo9uPkUKGRQOn9a6CW6Eam1vAjruDLcBfmQfTvmmptmzwHL8T1PBL/wTqVtC7yND5MQyGBPzfh2qjaeGriVUd2AjbuozXtstwGd1ZMxg8L049xWdqOlWbxtLbsFOM7F6H6im59mDwSS1R5Dq+kT6PNGjsGjkGVcDGfamwqo+Y8+5r06z0iG9v4Texq8afcDjIBrU1bwVpt3AZBCY2x95D901rGd9jjqYZo8ffDOOpHoKmzKq/KNo966G98KXVqrNbkSSJ95CuM/Q1zzzMGKshUj7wrRSRyyg47k8MBkUFnJ/rVgRKJI8ngVXguc/Kg/CnuzMB2wcitEZsuBFJ4HPalJyu3vVZZwf4gPapI5RuBJz+NBJMq7R9afHkGmmaNerDPp1pBPk/IpPueKYHsFwqsZJOmWOcdetJcs6slrEm7YA5Hck8/oKgQGZ2wRtQF3yeB/npUiuxEj7WDvwfU57CvHPrG9BQCspz8zEdB2/Gp0jBON25n649O4/Cn29qY/Ne5ZLdc9+WwOBhRVq1ktre3edYZJXU7V8z5QW9gO3frVJEOVloUdRJlZIk3Ax5wFGTn/AOt0/OmWVhcjzZZIWjhETgvIdq5I96nuNUuY7V2hKwucgeUoQD8RyTWcjSCylkncyGTbH8zEn1P9Pzp6XuO7tYfKlsilJbtQMZZYlL8/XgVmX01qsAje1e4CDCvNJtbHp8vb61PJtUKCuAeo9TWZdqZJss2Q3IP9amT7A0X7a4Kxk28FvAOpKrub8SatJcyKoVZPmPZRjFZVu6MgUH2FW48YZc5J44oi7kNIsLK8kbMzvIxOAMk5/wDrUkpWKHbEG3gcsO5PepISqoOc5yMgfpSAiP8AeygZ7D/GtEZt6kMiCC3O4jzdo49BWHePyf4vXHFaMrBkkZmJJbk+tYVw+SRnJPH0FKT6GbKch6saqXTnzLd88+Uv9akvHCwhO+7P4VT1JwtjaupyCGTPuD/9epSM5Mzp22SSvI2MBZD+fWqdgyvJc6k6t5MfEeR/nmn6msk80sEI+eWCNB7Zb/61F7cBI4bCyyba15aQDIkk7D6VtFHHJ3YzULh1IV2b5BudRzl27fgOKh1V5mcqqtghWY+nH3RUkOn3E8+6ME+X8zM7ADJ/ib0qzBPHNd7bKRZbzbzOykxwKOrKP6mmxItaBpawQT3F62zYuXZusY7f8CPYVXu9Ua/uAluuyNFKxRD+EdMse59TTby5+0xfZ7Z/9FiyVVjy7nrI57sf0HFZ7JKlu8dtCxZhhpB1b2HoKQ9iXUJERIPLJYhOXHQkVVjuS3AV5pie54FS29hdT2kQ2BVWQqSTgY+tXbSO1SE5mXamQ/lL/U0WC42K0nvZAriNQoy23hUHuar311FEDHaPmJ8hpB/EfQe1Mu9YMhS1tysNmG5jAyX92NVopR5c0aoFVGLjPJz7Gi1g5rg8pdgEXG0enWrCXktrEq/K6v8A8snGRj19qrRFTEZJegPBz1NLbwyXkx2EFurP/CB70rDuWraC3nmJtCUdhkRucj3wf8atzOiwhDkSxAZlAyHT0B9qzZrqCCJ4YjuJ+9IDjd7D2rPN/KjKYm2KD91eh+tNITmloWpQ2WfgKxJGDVaF/wB4xbrjGKlN1HJnzAhLe2MUx2hjbG3d0brQS2WmZXTgc+1RhHKkqVGPU1A92XBBXaPQVGXQgFh83YGiwOROXblWK5PbNRssgA28juBVds79zcmrKj5dynB9KoSdxImDHDHBr1rSbHT9Jt4fNs0uFVFXBQM0kjdMk9qyPCvgdhFbajqseGc7hbuvRexb39q7pbd3YxBo1RyGyBk4Hue/0rOZ6WCo680h7RbQsU0DW88PWNf4fatvT3tblPIeeSNVBIfA5Pofashba7UFwWluDxlzuJ/E1Z0bSrwXwmvJxbxoQyGIgsT6e1Yt66I9eNrXZsSL/ZyKLJ1KzKVkbGc/n0PHaqxjbaZJTkKPlUmrQDTySCdsqpJjwOW96twxCMo0katFnuOB9a1TuS33OaOntdJNcNKihVwUXg1RMlvaKkaxsVc5Mh6gjsa6fUfD99eCWQyIkCDe27gheoxjrWTbwNJYyx3CiV/ugHgp/wDWocddjqSjON27+XYy7W7gZ1MKbyCWIHGT61tLfR3AZkdgoUA7myc/TvWTZaMVu1juHEXy4DDv9PerUujXNoXktz5seMfPwR71VJu2qPMxVFKXukc0JlPmofmTpjv7Vx/ibR4725R441gkJ/eMF7e/+Ndne6i95dRlbZbWZUCPGvQkfxfjVTVo3ZgzKqsvGB3BHSrlPls0edUpX0Z5trekvphXcwdG+6y8Vmqxc7T97HWu61fTPO01+SSnIBOePWuIRRGRngq2w10U6nNoedVp8om0DKsAaaYlxkDAqxwTzTJR8vy1qYEsKqEzjFS8U2AHyhmkYkMcUxHscVqFsAXbyhI253b+72AHc06S6VYXW0zGiL/rM/OT9e34VUu7iS6lQTYBVRlVHAzzgelRyrujCrn53G7HpXj7bH1dm1dmhER8oK7h1x6mrM7hMREAlB37t3/wqpZ4Uu7jAQbvoewqpdXJxktkk8EdxVrRCa1FuXLnaGG0ZIz+tSXH+jRxW4+aSMbnz93c3Jz9BgVUgYJG15c42K2FDch37D8Ov4VCZZnIBjPPzFn4yfWpbE3dkkj723lQOMc/zqhdncGbtjNTy7ifmcYHLADpVC45bAJJJz9KhsLlq1AUL8vH93FW4j8wwNg/nVW2BZjk7R61oR/IQQu4eh5+lXDsRJkhDbRhcEHHJ6GoLmRZFVOi9SR/FUUtw24qGyMZPPX2pE2lN7nDdQMcf/qrS99DKTK95IyrsUY7DHUVgTPtZieccCtq7EsxIiSV89Sqk5rMmsZFQh5bW3x186YA/kMmk0ZNmJqDHZjpzzWVqU5GhlhjMU+P++h/9atXUIYI0bzL+L/gMbt/QVSs7S1nt5o1uZJlLo5Bj29CfU0RRlOWlhl+Psemi6z/AKTdqsUYP8Khcsx/Osi0ihjRXvJJBAPuKn+sk/3fQf7Rra14Wks0Pm3UjQRgxokcJcFs5+bB6eg9qzVsbVp3kn1FZ2IGVMTL+B9APQVo2jCzbGTyy3MAVNlnp6tlIo+dx/m7e5qzIBFpq29lG0UVx88n95h6Mfrziq5WGSVi95EVX5VCqyqB6DIq+kZA/eALDgbSP0NJ3KSKcVmxhWNV3EtkDr09qnNjFaoGuZt8h/5ZqxAHtn/CriLKzYwYVAx8oycUslmzBZSBGi8bpWAJ+gosOxVZvOg8p48w9Qg4X8qqzwCSPygwSP0Xir7xRZ+Rmc+ppEgAAJIGexqW9SuQw5tNgIUISOe1TQ2scciSICUweGPBJ61rbEOdqE+nHemeQzRjK4ouL2aMSfTzLcHzNy9vl6D6Ci4txBA1vaMckgyMeGPtWy8cyfNw7H14qERmQsG4c9jT5iXBHPiCWQFZIycdGqtLZSI4CkfTNdJNCQMAnA65rLuIis5dOAT0NUpGcqaMqRGV/mBFJGGklPy54z9B61sRW5mOXIjth9525Gfb1+lMu7dHVo7ZTHEDnJPLe5/wquYjkZmOR/AflHr3qPnrVhrKXblRwPeovJlGODQS0+xPp9pcX1wkFtGZJDyFzjivR/Dng424S4nQzXCkNyMLGevTuap/Ca0eDUpbsxrI5TYqsm4AdzXstrDJcWCmJAQ/LELz17Ub7HoYbDqUeaRTb7ReRmN1+eU7d5P3T3NXk09khTb5bbMDgYyKk0teJEkGTHkDPp/jWi5QacskjASo5/dnggD1FTLVantwoJLQp/ZopptpwMjaSv8AjU/9msqCI5IHzde3t7+1M8MwHVb17iaNktYiQkbHG5u5Irq54A8sUVptkCKQAvasE+ZCqP2cuRHO2ejzmErFujZSGyy5B9q27m1ik8qFVcTHHPTJ9a2bG5tQQsqscL+tY2p3sQuS8I8orxk5A/CtNErGUZTqStYy/E1nb26hI3uLm8ZSCqNiNPqO+Kg0kxxv/pESD5ScMM72/wA+tWJZZUuWb7KZN2CyscEioJY5re0E11HGk7sSEByAO3Hb8aILW56EYXgoMgvLJGkDxZA3ZGf4atJPJelIBDCsqjZkNy/uRVfTZbi5d0mXe2T0qWztLhkZQjLKQXB9vWtU9dDmxFOys90YPiPTXZXls43aeIclcZ29wfWuYaW6vIPLit2dkOSx459Ca9WvdHEFlCZWCmRNxy3zN74rlbTT5LNZ4Y0WSLd99vvc81DWp5so3WhyV1PdLpX2SayZJs/OQOW78muK1rRr6Im4W3JjY72CnJX6jtXsTWSpLF50iGNzhiwPy59a2L3RbT7MgtpY5FK43Acfh7Uc873RzVaMWrS6nzeJARjpU6EeXgg5rv8AxH4NTmRFWORTxt4H5elcJcAQyPE2NynBrqpVlU06nm1qDp69CNZQAFGaC2Tn9aNisuSOtMXg7a3Oc9ciISQh8ZJ4Yfxe/wBafNMTJHFEPu5II6k9KrMcxKVPBJUexFSWfCs4ObmRvLU9kUcFvx5+leQfVcxNeP5cMcMRJBy0j/3j6/nwPpVW1ieeRcKNznChjwPf6VNJIsv3QNgGAOgwKc4+zQOCcTSplv8AZQ9F+p/lT3ZLdkQXTxmeJIFLRx5SPP8AF6t7ZNVnlbIAbk8VFJuL4Bw5OMDt7UyTEed7Zb7uB3qG2wWiIrmdixHJY/eOaiVfMlDc+WAMgVFKrPLhTgk49sVehgWPChWLnpzwBSSuS2WLc9M/KueDU7SM75TcE6CokQt2zjjPYVZbMKjKsxPUY7VrGJnKRUjhBk657885/wDrVXvbto3cxkHtnrz7VJdztngYB6nHaud1K+G1kRySThdvWqehlKRNcajuVhdXM4RR9wE5J9h0/GufvdRbcwtlW3jP8K9ce56moL9bhstPIIm6jzJFQ/keaqtHbICbm7t8AZIDmRj/AMBUUkmYynYpy7rqQPIxEWcA4yWPoB3q9cX1rpllJHsaK8/hi2/NEuOST03HoPSqJ1uO1hL2O4SqMLNLjcB/sqOFH5msDbcXjs4V3kkPJPOT6k1olbc55Tu9DRi1KW3KzQAIrj5k6h/Zs9R7VtWemx6pbo0QGnynrG/KP/unqv0PHvVO101IEi3gyyqBwD8qn6960UimlG2WX5P7icD8T1qXJI0hTnIlMFno8myaLzbzHyrIMqD6nt+X51HJcEyCTb5kx5O45Cj1rTs4tkSxugmhA4SXLBfoeo/CryWdmVBSNonzyOGX/Glz3OiOGkY6SyyYDytgDovA+lBIA27WPOeRWvNsjG1CSB6LiqyhJG5XA/nUORqsPYovIOdiFQfQUheIgBcr6sRzWn5EQU5GRUbQIeNppXJdNFJLiOI/uwTnqT3oe8wm0RZ981cMKqOCPpUX2NpD8uM+wp3JcCg9wx5IG7oKZvd8FlBHYCty00oNnzSTjtmppdMgHCjIFPzFyHNSFjwI+fc1CLfzSQ0QPt2rohYRM2EBz/KpBpcjcL8v6UXY/Y3OZOnTE9ip6A9KfHpD4YyEqvsM1uXFhdQDJw6+lV1mYrgOUI4KmnzEuikY/wBhKttMnyjvihdNhOWfJHtxWusZZyDj1zWjoOjzaxqSWdvtTgszv0VR1NF30GqUTrvBul26adYxb2KOPMfbxjNd04lULa22AM5GBzUXhbSYbKz8uMeYoPG7v7101tZeW8k/l5mjTJAPqf5Vpqlod1NpaPoYyaabLdJdMzKy7srwQw7U9rYkGd5BK8wA2E5JPv6dqsXc08u2Jsv84xH1DH2NHl3kty0dzazWrkgBSPurnB/CsXdJo7oyly3bLVpCWkbZkt5YI4wB7Uzyp1tdykmcnGxDyK2ILKUSiF2XAyq+Xg7V9vepN72azHYpVSCQcc46GiN09TnVXXTU5WW8urdkRwmQ43YPVT3z/SruoL5kSGRFEDsWaNu/pjvWLqviWN9aSMRRcZZmYbF2+gPrWzpSpq99JLdN5WwbkQ/dZff1HsKlTUm0d8qbppTkrDwgmhMkce5lAXOegrM1y0cPbSTKoaUAnb8xP1xXTTWS20R8uIhiNwAHAPbisLVrtrGzuJtShZZgMoUGSMe1XzJJ36GdGblL3CtbP/Z+9ZMM7L1TnbWrbX1pcWsYnZvMjXy4iowcE96ydIgF9pqXT27vDKu+NwwAOe3uao2q+VIUBDMjlirdqtPS6LqUI1G+6Oo1GOS6kgiV2kEQI8055HoAemOlOiEdvE8MlkkoPR8nIqvatFD+7uGkWGUfL5bfMmfQ/WtDTL2FtSFtGjAOnSb5s/j3PenzHnTptKyWiMa/tPPQKsYx6VjGx1PT5RJA26EA5iPfPpXof9nwozSo53BgQuOCO9QaqkRgJjjUxlyASeRT5LnM6i2SPJNe1Qiym835GXIcMOleLNO0txLK5J3sTzXrPxGmtv7ZighbdlR5xHTrxmvHNQuEW4fy/u7zjH1p4dWlJs87G9EjQVyRSO5Dj1xUcUilM5pjON/0ruPNPZ4N0FgsjRhnZ/3Qbpkjqfb/AAqvLIYk81Sc/cB/vL/Ef8+9OErXVvGRJulkeTLdlAABb6dqjGbydIbdd5PyqvQAf55Jryeh9Le9yzaGMq9zcj/R4uCB/E38Kj69/aqNxP50hkdi8jHc2B39qW+vFkjhtYtgt7UFAw6O38T+5P8AKqLz+XGXCNjsBSb6DUurFmkK/MMIfTNVwzSPnIVQM5PSq08s0jjlVz2wTio286dwN/yKMHjoPaoJcyzb7pJWIG4L90A4rSgPygyPkf3RxVC3gMaE5AA7Nxn8qfPepb5aQAOBkZPX6VpFGbka092IEKqeRz+FYV5rSRl42fcOrDv9AazbnUjdNiOMsTnOOn4Vjl40JEhNwR0jThAf9pv4voKtyMm7m9cXUqxidbgx2T8LPu4b2x/e9q5291uZpCthGTngsV3O/wBT2+gqzazTs0gvB59tKu17fG1dvbb/AHWHY/nUk+ki32NC3m2kh/dSAfe9iOzDuKXOtxezkzmrm1uJZS4VUY84LbmB9v8A69QLpEzEM5A5ycnmusW0BHy9B7VA0RB5JqXVfQ0jhYv4jFGkqGUyys3OccCtSKHCgADHsKlVAzjNaFvEM54zjjFQ5t7nRChGHwopw2jtywwD6Ctm0sYzHhsdM8CiKFyMk9+mK2LC3DJz2HNEXdnTCh1IYNPQjp+FEtgE4Gcd637SERpwBz606S3JXcR161vyI05bHHm0bcflwAfzpzWCEdTn8q33tDnIHHtVOa2mb5dmAe4rNxsLk7nOz27hjtHApirM2A+T7dK6Yafwu8YA96tNZRrHhcE+o70Km2YSp32OTW1G0EqcdcVZSAEE4Yelbwt8ANt9hTJYMjIXvjHeq5bEOkjH5jwFBJpDvkXkEA+lWrizmCl1BJU8Dpmpre0nMQkZRtPBBqbNsPZJakUNrHEi7Bu459c1eMGVByAf6ULBICoG5R3qRY5MkBuMcgirWg7WKbjdlchgeuRWNf6c88oZDGp9W4ro5LeUgFiD6cU9LZCfnUE0vUiUXI5UaVKAS80Q9wTWr4Rb7B4kt1yTHLmLgc8j/wCtW0LSKTCxrlj36VteGvDjHUFmvIHiRE8yJT8pdu3uRVpdUZ8jTszrdOZXXa3A6llGK0hqAEZjjdip+UlOre2fSorBbUTyW94vlKU+SbnAOOhFS2Fsx2xFFTnJYc5Iq22dfJGO5Ru72KaaPbFsaNQCo4yw6Ee9b2nTmG38uXfJezHduJzjPasnW41R0WOGWS7YjbsGT15PsMV01nFaxt5sx+UHp3PtWKeuo6s4+zVkQxebZW7ljmdpAVGMceue9ZfiS6aGV2nVFDYOFbdu96vXN209yfsyleu3J+6KxtUs/t1yEiJ2R/M+eSeP5UpSurIrDwvNOZn3WhsykYXy3YM8inDnjGAfSug8O20ULiONQ0ajagZfuj2qfRA1xES8DeUMbfMHt0rTiRLWa3VPlAPB+vaoSsVXxEmnTkXb5zFbluDtUjpk1xMqPezM9yu5GBVWIyB7V2uoXEbW0qx4xjLEd6517ZzbIYzsZjgL1wfUCnu7GOEnyrzINPaOyVbdpB9mjHKdiPp2rNsbeO5uLl0A2bjwRzVS6ubZM2sczPcFsSP7elb+j6d/oBLMNxyODz7Vak/hR3VV7KLk3uOsdKiuY+GGUbGQf50viLT47IRzRFvMRsg+w96XTlltJzbrvYsCWbH3vrUWoQ3+pX0UMpxExC43cnnv6Cm5pR1OLml7S7lobgvfOtldiuAgDA/xDtXD+IddMivBY4yerAZx9K2NS8Pp5U8M07YOV8rcdp/EdK46yhTS714MuIs5+bk0uZt8r0OaMIpOUdTmtT8Kl7Oa4lzl8scN+deZ+L9PRIIJba2WOOMFZGUjk/SvoDxJq9qlkwuRg7NsYC8kduleH+O9atm0uHTLaFUfh5Cp79yT6n07VpSg4S0Zx4jWF5LU46DgBWJ9qlhO847CqqnMPU8U+CTamcHnuK7keU0e33Pl21nBbxcIIDuI5wpJOPck8/lUFxK1nbm0gGy5lG2Zs5KKf4Pr3b8vWnyk2c8txI+7UAMKowVtQTgD/ex+X1rID7S8hOdvc9ya8t6HvJiK3lSSBFDscYJPNMcvv+Y/nVfzgLggEAlev40wvkb5HwgPXPWo1YnJIsPgZw3zHuRUJmKZ+Xy1UdWrOuNRVOVyVB4OaoXMk+owZZ2VY2woXjINUkluQ5N7F+/1+KJNkZBbsR3NZUktzdHfIWRfRuSfwq1baeISGmXYR2/jP+FSkEkqo5HHHShzBQb3KogQKFUHaRk5OSfrV22tASCenWn20RYsOOBWhFEUTAHXvWfNc3jTKjwDhUHI4OKuWRNoGVow8L43xMflb/A+/arCQ7QM8san8rep5HPXPalqaxp3M/UYPICywZa2kyY275HVT7j/AOvVEWYbDNk5H610dnbJIz2r5eKcgj0Vx91v6fQ1GbRjIN67VHAHeqae5tTpPqYf2JR7Y5ArRtrElQQMkVcmtcEYAJz6Vp2luoXf3PrT5TqjRs7lKO22quFB96nt02scDIrTWBgnyqCDycVYFiIoDjBJ45rSMOxv7qI0wwUAEDFSyZEKhOp49aiij2KCTj61owDI5Ukda1RnOCWpBb2oCYc5PbPanNbIThfl7cVaO0MdxGDUMkgV+GFUYcjkzPubRlZsfXNUTGw3fKTjmtmSQue554BqBQruQx2nHOO9ZyXY1jBpGcZBbxAHPTOBUbTJIFXhSeanuYOBtHyjtTEjVx++UAeuKzXNccqEWrkcRikkwSxx39KsbYwQNoI7CgJCkuV2lR69qVSHdVX7vXJq+hh7KxBGpkDn7p/SmSJKFy7EAds4zVieWOE7YiGXuQKSW4zbgLFEkW4/vH5dvx9B7VBlOKQ1LV2QOwIjx99jgCgywW8O5jlA21hxu/Ad6pLqRjdmSGNyehYZUe+O/wCNVIiXmLHBJPXHA+lPQySbZtx6sIjtsbVVjGcSS4LkH6cCobm4v7n55btyykFcHpjkVCtsqsv7wsD1wOfyq4vlr2Lf7WauL01LVJNncaHq8N7DGwnjF1t2vE5wwb2z1ragvIbZzJKPJU9RjAB9q8suYY7hd5j5HQ96jkikmnjFxPLKFOQHckCr5rKxcqXNoz0pvEtla+I2E5kjhkjCrKBkIff2roLqWzEkUNnNHJMy7lKNnGe9cHoVpBcsoljD+5rrNKtYrOV0AUAnKkDqPSs5x6nNNRi9OhrQ2hth+7dmXoT15781pQ6TavbtIhInUZJA4YelSWzC3ASRHkhkx0GSp9cVddY7dyy7GTGFAOB+NStDmlVl0KNhDnKbwAn3Qe5NUNfgbajI2SDgEVozwsCrxtg5ywPAqtPIkkyxtuVGGQw5zio1e5UJvn5iklqY4BHhzITySeKSWxR7LzGlaNlwGx6dyDS3i3DKpjUheuQcZ+npVlLiGSLZ8pYryrcYoUlc255LW5xV3p8Moigt4+AS0srDBc545rfgRreJNhMYJ2ktzj3xV82NvLJHEp27xtBHGP8A9VWbmwminit2HnW2zLuDgnPQf/Xqk7u5vVxamlFnPb5m80w7mKMTvzz7/WnzalbWcDveTCFwAVY87j6U25inthcW0QVdzkg46djg0zT0isWS4vYI7hIiFKMPk5HX600uxcoxlG5rXE0d/bR3K/ekQFlTp7Y9a841K5V9Tdg6BgwVgx6c+lbV/eTh3FrM8ETcYXAGe4AqC60SG0sVk8p28w/MzJjPGc881drsyVJU9+uxkeKxbW0aNbyrdkqAwxjBPb+tfPHiZcaze/KVzJnBr3iVGWKSKZFWPefn5JPHH4V4x45s1s9cYi4WeSdBIy5BMfoDXRTTPMxySSRzKSYwPWrEBIwTjGKhmREAIbL459qjM5A4Fbo8pntH2W48gRGGVm/1kvljcE/ugkfifxqCXTdQdQY9PuCgJ2Ky4J9yDVaTXLyWNvOvpUifny4jsDe+Bj8zXN3fiiYyeVDsvHGR+9G5QPduv5V5lrnsSqWNueyvkec3FnP8kYJEUZZgM57VgzzSXbhgrw7eqOPnx9KuadGLqRbyO4uLG5HyhDMwQn/ZbqPo351rJfag0rRamiXaxjHl3UYYqf8AZb72ffNDsthJORhQwq+GkVnxzl2qcNKSsVviMnlivGB25rWeztrhMxuLOVuVhmbKH6P2P1/Oq0dnJbStFOjxyjkqRg/596zbaOiMV0Ire1JXk9/z96uC3GM8BByfU1cht9v3sdOBVtLVmG3gZPNQzpjSKNlbkkNtChuQMdK0jCu1RgFj0xVhLYqF3D2zVgQbCo6t7jpVwRsqRnJZybuSMhsYPpWhHaCIqTjHfPerUMAadiTgDqfWmXimJlYOxJBOw+laqKSuawj0GJBtG9V5J4AHNLfRCK8lJxvJ6DkDPOBT4ixCk8Mw7mm3kTSyRSKQQYx37jIP8qOhvCDctSjLhxg8HvzVizJwisQF6Urwhs4HzjuaS2j3x5J+Ze1LqdqgrGkHPA6mpWuBgjHzH1qsikgFTn8elT+Q2c447/T1q1oZygupIuBGcDJ7nFPt2IAQkjHf1pyRMy/ujkkYIq3Fb+WhL49eOlWjKVkUpf3jFkbPYE1W3yKCrLx/exVhnG8YBOT6dP8AGlQK0oEi5x1BNG5VrIZCC7Djg9OM1aFqjLvxtOecGmLJ5cmFxjtUksqsoTkZzVLQyk30K0sY6gfNjoe9ZlzG0wKIMY54FaUrgKCWPI4x61EY1GGJ2getTKN9CfaJGdHbeXH834DNVpVmHOdqdMCtN5BsJwN386z7uU52nGOo5rNpJGE6rehUmmSBAAm5vWodzXC4Zdo7j1rRtreOU5ZsNnADDg1K1ogaTy3XADHI/hx/OkkzF3ejM610+a5lVIY3k3cAJVu606WylEM0ZVgu44OeK7Lw9Lbf2Eq2imOcAiUPglWPUg9xgdPeqmvahAts1sUQSMxMjA7pGUnIBPQHgU+VJERk+ayRm+HNMOqX0NpARK8gOfm2bABkk57D1qa5tFjuZrZWT92WDOD8uB796yLC6eCUbVwrHlScZ7dRz0rfgV7+5muHJIVgqxhMnaBxgDjgCnT1RrZqXkUYoljjMjkK2OAe9VIUMtwzjkE4FaOomMyySRo0adFDHJ/E+tV7NNrAj16Vb7G6XU6HSMwCMf3uv0FdRazrOyK4OV+7t7Vz2lIJJWO44jTPAzk56fjWzpzN9r/dEqCwGSMYH9BVnHUhdtna2MpmAxjKDt3xV6SO3QCWeHzFHIUc1n2a+QqAN8u3II9a0FlDEkE7QQOnSsGeZLfQzoblXWRZ4/KG4lQOfl9PrVOFZrqUtIiwqM4Gclh6mtqSCNrjci4J5JPemaiYYZECgoGbAPUkVKVy1JXtFblQBLZApwwcHaoboa5+905bjUYZNwHlgnAOfxq+0y/ariGVSWiHG04LHtioZZoGt40ZCJ2bCnHJqZwvudUKcoO6Nm02mJM/NsB7fyNaEaRlmkY7nK7QD2FYUV8U224YyNtyx6c+hHtVDU9QkSMqk4M7KQpUcJ/jVLRGf1aU3Y3by3BQMMMSOwFcrq1jKtpKAXEJYO0YPUjvWnZX92sEUdwEecj5wDkE+1RXuprJbOt0ohzwwb0qlLS5cI1Kb01ONGmma7D5fkfKu7rVq5aaSRlllefeQoLnBHbbWrpV9Yy3QD7ZkQ5VlT5QPcU7UjG3mTRwGScNvRAuATnrVxklqjarWk5WkjkNQ8NC7vJhezT7lbcI4pMIP6H615x8QPCNrBpF/dW6KkkGHVmPzkA8g+tex3Frd6lbSuP3CknIHU+oHpXG+J7PSP7Iuf7YuGjtY+XUEhmOOFJ7A1rBnmYiLd2z5wdZXVPJikYO/lodpIZ/7oPc8jinXqQRT+TALgFVUSrcKFZZMfMMegPTPNdFdrZ6zpemxwa3a6aNPDRm2uC6qDvJEqFQckjGe/FYvjDUYNR1cS2073Ajgihe5ZdrXDquDIR159+eOa6FLU8to25Bc6mpM2+OF+Nq/eb0Gf6VcttNhsoiqf6wHbyereg+lXS3kAOGwQMAL/D/APXp8f7v559qHBwh7A/1rzpPSx6kIXd2TQ2+6GNMExgbQPU+v4mteMhES1lbIUYV+vl+3utU7N5JHYKAp9MfcHYfWrJXap6c9KybsdcIXKN4GUtGwwe461r6OVeBIr1GkhX7mPvxf7p7j/Zql5f2lQGHzxd/7ydx+FbVvbFIkQfcIyKmK1udEYX0GT2kltOuShVxuSRPuuPUf54q7aQMZuDlBwavadbqVNtMwFu3IbOfLf1H9f8A61TGE28xiICMvDfWqUNbnXBdBogXzNqj3H+FQXTLHKSGxnjOcirbE7WPPv2zVG5U43OSEXqfWrZvGHcZ5zCUJGMlhx2z/wDWqVoco8krbnGBk/56UlnDhwzffPUe3p+Faxt90IfcT/d+gprXctRtqZ/2fdGcknA4Hp9KsSQqbOAnjY7L+fI/rVyWBFhbaG3Ej5s8LTTgaTdK+CwdCp9s4JqjSK29TMuFYp8mB9fX1qCxheSRumG6+9a32BmtGuHbYNp2gHknI4/Wo7KMiTLcLihrU6FJWdi5DCiAKFO3qRSywqUJXIPerUYBjznOeD9Ks3OmT2yxrdRmPeMqD94D1x6VZySmk9WVbaGNYlC8Z44q3NEpiwOgp8VsERcfdHPJqUxhF3bsgnGKaOec7u9zFuIkiXcfvE8Z6mljXMf7zBxwOKtXNspkUsjZPYelXbLTVmhZopDIQNxQLyPXPsOmaaKnNKOpjTwkqGA6A84qi3muSqq0jr6DPSunOnT/ADlon2qOTjge1SpoaOnlybt7DAaLgDPTPqKbMPaqJxa3LguNxwT09D64pLx1JGzkYyzN/St/VNBn0QeVeqvmy4aJhzvHc1jtFvDb1YbTg/Lipu7CbU1eJkSF5HIU89sccVq6n4U1HTtPs7vUIfKiueYk3gu3Gc47cetQpKIX3Kg3D7rH+HBrRvNZudTkkm1LbczeWY0f7oQE9QBxmo02E4Ti01sUbO3lnIWNZBBkthMDOOuCe9Q6kjqdzKqAZXI5LY67sd61bW4ttwhjkFsrYXkkiQn+Js+noKtXFjYOm68lfeDteVF+Q+g/z9KloTnZ6nMW2oPDbSQIqmNzklhkg+1LckyxCP5QAMnA5J9ailMa3TpAxeNe5GMVKlwnlOrqMMe3BH+NZ38zZJbkNrAzuA/QD71drI0EOlxDKrMybWSPoPf6dqwdJjSclFUMCpIYnGMVqXkRgdIn/gUDHt/+uuimrRJnZtIyb3JKKAdo5wKu2aoISVYFiMdP0qtcDdzvyPercS4wqnAJwfpVoroXtPljglzJkpxnHv3rqXimgvmuEXzreQK+5fmxkdKwNIsknlZJXeL5d33ckenFdTZ21zBEEBi3AbVYZ7e3YUHPVkr6GjBq0CbckbCQAGGMcVo29zG6kqzMM89gff3rlJy8WfPtT5ecZwcZ9jU9reMqFd21B91SOp9B6VEo3OOdFNXR2XySAEE9OAKx9fm3RYiZllUcBeMVo2keSApLADJINJPp4klWTA3Bt3PrWSTuY0ZRhO7OUubO9uJbYXUYgTAICA5YdiT61Ya18idZmfcqAgqOdg9TXQakZ5gu1ckHBOOAD3rHkaNSFZvNCjZKQfvHt9cVUkd0K0ppGSXmkeOSKKZtrZJ2nB+lKZVnXzLt3ExchYuNuK083lgNkDMkcpyxPP4D0qvPEh1RDbrvLdFPJ/Oi1kbqon0Kuko8EvlzrtR8kZPIP1p8kCz3LSgrcKG444H/ANetPU0Ro988bIf7q9c1T1e8+zQKIYo1RR82OpPrTSRi5uo7rdmdeIkjKsaANIQikH7vPetnS0325WVgXjO3aOeh659KxoWZLYvIGEBGS6qCc+mafaX8NjfIqndDKpDMjZ2575NNp7mVSDkrLoacF5Fpl+8U8aSLJnCAFuv8jXlHxYuY49O1SRYR5LIPkZR84PGT3613uveK9OsSq6fE8pzlpccs3bk15Z8Tddjewa9vfKZpcKlkV+Wfno5znaO+PQVors46i5U21ucBZHWE8O6WugXmnWkRgPnRvLCsjS7jl23cnIxj0xXD+KDqLas51ieG4u9i5eJ0ZcY45Tiugk16yJz/AMIxohP+4/8A8VXOazKl9dtPFZ21mu0DybcEICO/JPJrZM8uUTuoo8OHPUHO49B+FPhcSuZWBIU7UGOretTeWJmSFOpxuOOtWrOFBM237kY2D3PrXnX6nsKN9EWbOAohfHLdeetWm2pH8x6Cktwdqdzjk0sh3OVXJJ4NZNnZCIumqVdZWByG5HqK6SGHyIWG7zE/hz19qzraFhGFVDjHHtWqNyxoqrngVtTVkdEY6ockhUMeFP0q9AnmW6TMCXH7tt3Of7pP8vwqAKuwZHy/xCp9JLyM8RUhXQoq9gRytWdTj7tyORSjBWGeeMdqq3ERecgZaOM88d//AK1X70MGgSJ8TY6Y+6PU1IkR+yrDuCooyABz9T6mh66FxaINPQMQzBQufxNayQeZGQCIy4OWPQDFVbaHzWWOIFCxwd38RqQQSTRTZZtvIO31/wAOKaKk9SHYblQwXy2VRtCc7vc+9QSQKlvdu44ZVH/As1o2wCIDjG4cgdx/+ui7iLwSRK425Df8CPJz700tBqdnYy45A5QO7hRgey1digT7OJWb7rEH0xjj9afDaLHDIGB81yOc/L+NXrawdoJyGTZF9/HO09iKepVSqlsP0m3B1GBVO4BldueByOK09RuDqmtbS+I87FbHYdD+dUdEZGWNpXEFvbHzpC45ZcgEDv1GKTRb2Aak95JFmLLBE75IO3+lCaOGesnLqkTmLKqFPzKcA+tTGIraBmeNU3cjqzHPX9afakFhjJJ5z2q3cWsbXFrkDe5EhJPQVRg562ZVXCz4WAvIAVjjYFjnsfr3p8S+RcwlSQWbY5iODnuCPrWpawquuTQOJN/lgrtOMYwSSfwqOULcud6hCk3Dg9U659qZjz3ZYe5WeERvtTy2PLsMM3TJ9qvWzRfZIj+5WRcISisVZeOQf73bNZqyW0kE0qMiEKA+RkqO5Ap2lalavONrbIlUtM5HAGMAAD3570rmc6bcdFsM8XJaDWhJMUJ8oKpPzMiAcKAOhJ/IVwPiOFrW6kVC2WwS2eMkdB6ivQWs/s+pO9wJJ/kDR5XdvYjjgdBjjFcZ4sQvrDxP92PGFAwEJAJAA96lvQ6MJZNRWuhy1vZvPIEjVpJDngeg5Jrp9F0GGWyU3abmuQxXYx8yML/EFPDA+nWsyxs2k1MINwgXljnAI7j8a7O5tJbbUGhaNjBbKAr7cEDGRjHQ4z+AoS0NcTNp8qZg6Fo8Mtsb4yxmJW2KMcse5OelW9UeC2sZlKIsYU5yM9aW8RvOeeOBYo3RYmT7h46kDv2/GuX8T3xVRYoACvyuO4PU/wBBSb5Uc6i5yKFtGbyeQWsQ3O3yIccKPftUNzaNEfMdCqsDt/Cul8MaSLiPbcRho2BCFh90d29x7VzV5KBczRrjaWP3enX/AOtWTjpdnTGV20jQ0WKQGCRApYOGAPRjnpWvr6eVdt1MmMyDsH6kD2GQKZpPkhrYOPLRcFmXJ4HJP6VFq8zySvI2AZWLEexroSsrCTvMowYeYb+E6cVpworgbc88VQt40aHOfn/lWpa8EADvjGKpGjNrTSI9UtvMYyptMZkHGNuCee45xXTxNGLxUIUAr8zs3yg/X8uazxp9u9vaTCQLsK4IYZAPBJ9R3q4I40mKvHDKM4ZnIwx6celB585KTL9/OjwLMkbbY3ChtmQ/rj/GsJ0maWWWGAoiAYBOS3uBWtJcOVIXdGoXbknGB2rCMs8MVybaDb1R3HzbV789iT3pCpx0sjq9EvlW3jYoz7+CqLk1sSTRhQMg9h/hXnuj6ubN1RgQmMcevqa6u21CK7j3RESADqKzaszlrUXCVyS91CJV2SlYS/A3HGfas+Kx82bLlUt8g4Wi/jjnga3vrZTvYKrdSGPQ+1LbafNbQSrJcytcp9wnnPoMVKuzaDUI6OzF1yS5BYWxUxgYZODux059aitNskJaZEjdeS3pj0pDHdX1utoAIyDmQdznrVK7gmhYWs0rCM8DjGBT1bubRty8l9TodFtze2st3OwlaRiwGOi9vwrlfFltcuFO5VIbAUDO4e2K6BNWj06yijtkWVFXYQW79s1yepandSX7jyxGu7JA6sfRfSrtpYnDqftHJbFTN1cwJbLE9vHu2u2/PzdvrV620u505BNFCl38xJWRcM3rg+1SXVoVhtjHdmJh8+1eMHPIPqay9R8TnSLi5mmuYYo402qZMjqMnj/Jq7WZU6jafIeZfFHXNQ0XUXhWKHbcr5sbEAhR0/OvHdVuZ7u7NxcTNM7gEsxzj2HoK3fFeuXGvavPPcStIqjZGWGABkngdq527yoUEdFHNNbnlVqjm/Iijtbm5eNLW3lklkYpGqITvb0HqafqgtY2FvHaXlrdRYWcXDgndj5vlwCvPT2rr9P1i2Tw7FNBLdC6tbJrFY0gYxwNI/zz7xwMqenXNYPimeC+1LzIHlljhgjtvOmUrJKUXaXYHkE+/NWmcrVzuIre8ihMkm1/9tFVsL65FKjBo88pxn5OKrxyN99SycjG04PtWotzJLblpQjMCEJZQd2f615jaZ7kIkMK5VV8yUYA6kf0qVLdNwPzNzyQ5qeNoioDwLk91YrU8axBuEkGepyPyqUdcIrqT2dtBgZRD9SeK0VtoP3eViIHvVe1j4DEEgc8mtiLBA6ZPOcVvDY2tbZEJtbdd4RdznkFCwxU9vbzJIkkM1xEFIPLBifwNTkh4uvPXk46VPHt8pwCcqMgfzNaWK6ajJ4BDcMuCBuOTnJbmrsCAN0IyvT1NMvFJu5SuCwbIIHX2qN5njCMGZW3bQTzijYcZXSJYHZT5artlLbQzdFNXtNtWC+Xu3vkqOcflVFWaOOFi28OXIUjkHoT+NOjuWSSORcAkZwwwPxpXsOTbWhIcQJtfCsp69c4NF/chBC7ox3AhsDJ6/4Uy5naCeSMlPMY7gw6HPNYXiCeWHUJYYGJij2uNpyWBHP/AOqhzshw95m7bzRyaXG8bsS7KSSOAc4xn9K1Y5JLUSM0eY2GZH7gduO9cxplwZ7FY5V/dqrBgByO4Jrcvbx4TaGUh1lKMVBz8o478dSKtPS5NTsYl6ht1tI5MtLOc/f52Z6H05q3qCRaRqUlsG8yJWDRsrdUIz+YP8qZ4whG61mAcLllAwMjuBxUniMiRbOdlRJxGFYLyGGAQ315rOS3Gnz8vnc6xoNjwRyLiRYUyEOcgqTnPr0qzpasut2q3CZywChxkfj7VleGBuayaV+JchiTnGD3roNcgLagWifZLwdwPfHUe1axeh503Z8jGxxSy6jcTXnyytG8TbB0z3GPY1harcPbW32baDIkZjY5zlTXUtM8TW7tEsEmf3mBxnH3j7Vg+IdNXzFm2hoMnoeTn39uvvTLoSXMlIwmvriNklysW5CqbOOOhHvmrmnIZ5Y8sAzMEKrnkD6emazXhkinW3nE0kKnB2Dlh0HH1rV8O2Fw1xGzkxPG/mrGzYULkDJ9M+vtU3O2tyxhdHY6Z9pOsyC6QBIFDMuTgEnIAJ7jqRXn/iBt+s6i8rF5Gnbk4z164r0DULpNJgvGuSzyPKW8sHlTjgtnt/hXmUjCUl5CzOckn39aGcWDjdup00RvaBpG2xjuXUyXF0khCFvlVFIwwHqelasuorNuE5RFlcKwB3BSuM9PvA47+lQaPK0ltAbXbHcbBEuTkNxz16CqV2wRXSRWBHCFsDA6DH+e9PYmXvzfMZniG9jFvLKHyqH90q9A3fr0rjbSI6jqWAAWY8DnA9Se/FdB4ph3Sw2URLNtLsx4K46sfXipvA0EFtK2oTKTArExhm5YD3rOS5pWNotQp3RrzCHQtN2rIY7xAUZJOhyPvAdj7d8ivOZgxlKSnLA/Ng9/Su51QC8heaZFRsiR2kHOM56/iB+FcZEfP1AqQQZ5AMFR90nIx6Up7pCpe6m3ub+iGZNKlkxtWZvIEmccdSPpVfVVAWNi2QxI24+7jv8AQ1ewF0jT7aMiORHkkk3HAB64APsKp3+Pt8kYbfGjYR2GMr1BxWqatY1p6u5Vtm2SbTkL6jmum08rHFGLtQkThtkoHKtjgg/zrChjXgcLjJretNORrZg0yoI+OSTk+ox1FXcuraxph0jhMLKjieEAeU2SG/2fXJxxVu11xEjRGtgVZcSK65f3BHr/ACqkkRtHUNIhwQVZSM/UZ6VAl46XlxBPPxNmTzIl5PPzKD35wfxpXORpMfPNNLId5kFsi8L3x249PepDemO28iFgqk5dhnn6/SqN3fRhmCKct1LHJ+tU7mdZ2UsFRAAmE9cdT71LkkapX3RfguszSG4PmiQYzu259/rToLmW0O+13K/Xdu+U+xFUZGjQDOSdvbnHpSW8287NhGOpbnikpBKKZ1Wk6pNqEbvcxZSPBZo8nB9a6CDW96tvhYqAdshPJPpXnMV5NZ28kVo4VHJLleregzWna6lZ21tAk90Jp35frtU+9Fuxx1aSb2Ome7e4DzQQyb920KOpPrVLVJL5pdskQZ2zEvzfdz3Jpvh7VxfzSJEqKU+XaOCB6/Q1NrV3Ft8rl2kIQBOu6nbQzjJRlZo5HUZ2S4USgrIp+ULzk1Np0F5qlwRIwhWLBLY5xmtLR7SBonuj9nlmyUOeRnOMD0qPW4V01zJKDDvHC7sZPpVKPMdM8UrWjuZWv61LbwSNO8VvDAxHmJyD75NfPXi3V5dX1SeYzySx7z5fmHgD+9j1rr/iP4lF/KNOs3V4EO+R1OQzf3foK4VUURsGQM3XLH+lVJrZHmVpt6GXDGZWEMW/zGPQDPHrRehg0gcpy2MKcnFXpJJIYLiZ32Bf3UaqMBnYc9PQZP4is4EoAdu4YwoHXNBzHYaRIuoeGPsNhfWtsh094JLaW4ERE5kDeYc/eyP4u2MVg+Lpor3WP3M63Tw28UM1wnSeVVwzj19M98ZratYbsaNo7aN4fsNSV4j59y1mJnEm4/u2x0wMcnrmtHxLY272l839n2dm1oIAkluoXEzj95ASOGx1z2ouTYtT2oZ45hlLdxu/3W7qKeSGkQBcKvQVNYMLqGbT0B6eZCe7SL1H/AhkfgKithv5J5PIrzpeR7tNdGTxJ8w54xyK0IgoUHuODVREx8pOSe/pWhaRjaVJ5HNJHVFmlbxELwOMc1IodZRgYQDJAHWoLaffheS44wO4q5K5MkjZ/wBk84yMVrdWLT11JVb92WcHccY5HIotpFM5XdncAMetRRlJNx3EBQMA/wAXv7U2F8XXnnA2AnI/QUcxfRmrcTfNK6Z+8cHuDWe122xS398Fs/0p1wzIh25OCrHvwf8A69RWkSS3jpMxWIkrwNx/AUOTbJVki6iNKFdSV8tsY65z9e+ajnYKzq+eGIJIz9Kkj5gAJLqDuxjnPtSzOJJEMZDPIm3LcfMP/rVT1QlLUjuHACsHZpz1Uj2GCKz9Z88W8FyhTzWJGVH3T3z6GrltCwClizEAE56ce341o3Fus+ntGET7RIcJgY+Yds0rXRXOotGb4dV0j8pVEsbkMV34kU4wwA7+oqd5GYQQskjtEXUuOc85HH1xn0qtpSqt0I52NsrEhnUZwScHntj+lWdRjmGzUI0EYZyrqGztYcZPpkDNXF3Vi7XkakF0L9ldYlPkDzCWPRuMe2fapfE1sjW8PkNv287z12kcA/TFYumTG3W6cQlgV655Fb1uRcaDOjhhIkgJY8/jV7rUzlF05JroavgdobuwazZEOwbyOhbBPr9a2fEETWsMDx5aQKF5Pb/GuM0RzZuxVhhuCD6V2VncNf6TNI673hYP8x4OO34801scWIi41edbDp7kagYnjDSMsW3YD936/Wn6SkdxYh5JNwVsNA7AZx2rEsNSGnzNIU3HnnOBn0PtWYLt4blifkRzvBUdPb3o5hqi5LlWh2ptmukiFqyxyO28hlCogHfccE1H4h09rTSJZmEFxqYUpI8Tt8qZ+UqvTOB09qyodfezjllvNkssiL5BKqfLHfA9ap6xrsUunQR6fJJ5rSLLJuTABHbpy3r9aLmcaNXnXa/9fIp6lq66hpUAcobsn95IMjKqDtBHrz1rLjDCMeWdu7AJPQHPejUmjChFWNVBONi9MnPXvVW0uJIpUMb4ZSDz0/Kl1PSjBKFonVaTfpB51jM4jkWHZEDhlL9cg1Oltu3iWNU8qISEO2QxHUCuSkui9yJyF3eZkqBx15rU1TXGj0swRsFKncmTlwP7uR2H8qbkctSi7+71OR13UXl1C6cE+ZIxjBB4x3xV+zniuhp1ivyW8IxMem7vWHbxifU0VyixqDIxY5AyM/lWpaWkaWP2h5GhMjcKq5Lp/SsYtt3NZqK0LvirVPMtEgwo88GQ4P8ABu+XPr0zWBozGWS7uGMeBHtXccMeRyvuKpapcPe6iY4S7iRhHGSPm2jgcD2q5eRw2U0Vtb5cqiq2cg7+456Yo5rvmISStFHSXdzZ3FtEshOY4Qp2jndnPfsOcmqU0TLPLG7CR1bbvHO70x+FUIWiPli4m2HzAkiqp3Kvdh6/Sp7VsRp5bZIOATwSM8VcXdmsFbYsBXEZKkoen1q1a6he2jhopNjIMcj7w9eajeQlASpJJ5OKR5ZSQ3kKpAC4HQ+/1rRluzWpcivXunZ7jaRngHj8vWotSvAkSm1yXjO+PJyM9x+I4qhcPtbauQp7+lRKrOwDAkenpWTl0MnFAl75xJVmdZBnir8bqHJGdvoetZbQGCYLEQsMnK8fdb0/HrVuFP3XBJYntUJPqLoXnlMilogMA9N3Wp4mJGQQGI574qlBCsZ+Ztz/AKCpWjJH7tjg859a0iGmxIHG4gcDPKj+dVriNTuboPr1p8UIRiWY4Hb1qC8cSkKeFAJY56D/AOvWivYiTtsVo7+4068jurCQpJF/F1BB/hx3pmp6pe30z3Fw4twygFImwB759TTZp0BVj8o6IoH64rKvbhBuacgheidqqyOeTS1I1v7q2WQWN1NbQHl5A33voP61x/iXxFc6lc+VJczXDKoUs75OB2z/ADqLxDq810TBbnCY5YHqfasJE8qELnMxzk+n1pXOCpUvoie0TLmTAxnAA6DH/wBeptjXLmOEffcAH1P+e9VhcRgKiN8qjAVRkk+lW/tKWaFJA3myDbIeyj+4Pf1/Kg5zO1i382SOK2IMMAIBJ+8f4nP1P6YqosKRR5DFpCOT0H0rUkY3bklVVFHCKMY+tM+zLySOtO5LOm0XT9MstOgY2d1Jdy6e9+zR3bxJJtbBjAX0ArK8U2kNrqKtYwtBZzW8dxFGXLHDLnJz/F61qW722kaXpb3t5qjTENcRfZSgSEk7SBu6njmsbWr6PUNSknjlupAwUFrkqXJA5+7xj0xQJI6G0kaOVJYztdGDA+hFaVzs+1l4gFjm/eqvpnqPzzUFlBaRgedN5p/uQ9P++jxU9y6SW6NDF5YhfB+bccH/AOuK4EtNT24vUkUcEjirtorFMbsc4rPibfg56961LYqu1cDI754NI6Yk3lBJA30A/wAKnheQ3BLK4KtjaKcIxK7Rp97bnOc7jTYN0czdfmGRzVWsaIl5UhsZIIbI/u1YlANmNoKtIpOQOCQeCRUS20bszF8KPv8AqB/9fpSzEO/OAuQTj+Htge1C0Q07jbMb4SHYl84I7j3+lPYKJUnRwD5hBT/PqD+lGqKILi3nUjDKDI2c4J7H3xUKsGdGjbOUDH39ae2gN31NS2I8vJwScJlTyuOc/XGRVzEU1u0G0eZHh4W6HOCMZ96y9KuGjlZWIIc5P1q+6iEypIfN2fc4xjOCD71otjFqzKludzq6x7uMYBxj/GtC2B2SBgQFOQzdmUjH/wBemajGFnWZGxDMhkIUZVXHXHoOlPkk3RKY4yiEbSW5bjrn69jQtC73IrtHkvJIoVSNZX80OW4Ibt+fNZbGSLUJo7st1+YhcZ7Z+prcni8+zieJcQwkom89SfX2zWRqTCWO3mRCJBmN5A24MR0/HFBvRl0LClVAaNcq+VZS3cV1fheVJ7ErNAQxj2lyOfQZrk9JsTex7opF3qS5DduMAZ9Tita2C+TKz3pt5yAWXnbIMAjI9TWiZniLSXKmWruB0wgAkU/JG69WHXFO0rV7izMsUJwzLtZeu4Z71U84l7YrMXzz3GD7U++Jgl3wtG7yoGOz+DB/Q8Vb2MpQuuWRa1FZETdNERG3KsBkH8axmu02kMHLdhng1bm1OdoCs5ZlYZCA8An2rEUlpWO07sZ5Oc/SpbNKMWl7xcm2sWbBG7qOppqSYMas42qTgHtn+tNiI27jnP0qtLhEbcee3FFzq0tYt6luAHI/CqIO1wWON3cf1q15jPCu7HFQxRBwwYDaOvNJkxdlqNV/KPytx61m6jccybGJ3HuACTWjeBVtGYEDGM1zUhaWV3yoVO7dz61nN9CZSW5ZtZRFDMrsXZlA388v0/IZ/Srmq6uHhWOCMqqxCLeGxxjH69xWXHKIo2SQksw4UdOnU+9ZtzL5SseSQfXuajmaWhyStuza8MWwmv0kuGXyxnJ5+UAE8EevTNS6oYvtKO8ckcbOGLZ3ED0A79qtaZB9j0CS8SZoxJiMJu5cn72R2FUNUk+0LHuPI56Yyap6KxMd7kkkjzwO7Ss7PJklvXpn8q0bZAdqoAT7msS3YG3HLbsjAHTHfNbduckZGCOpFawRvFlyIuQVUDHQjNI07KgXYMDoTzSGRVxtH1qOV9oLNyT3BrSRLYhBkKlgMZ6Cp2ZVUeWODzj1qkLoICWfI7qKel3Ez7VZjzgDGayTSIbLMrwSWbo8nlk88DkHsR71DZ3LSpiQbHU7ZAPX29j1pZHjBDsylgMetZ91c7ZBKnLjhl/vL/iKJMNDU80AEIeD/ePNSeeAdzNyB61ix3yyLvUjDcinSXZEeCiEZAORTixSkX5bssdyBQp6Fu/4VkPfOxYK6HJywxwfQfSob/UomBhKsruD80ZztHTODWTqV0tjahlYNBwoZecE/wB70P1qrnPUqJFm/wBSEAZ52Ge7A8Vy2rXk90NyuFh6lQeW/wA+lQ3ErXj4fDI3AweKrwBrZmgVvMjb+BxuH/1vrQcNSq5aIqkRqfMDfN0HGKpRWsk9z5cb7iTz2z6CtyG3h8iScKFbd1l6fQHv9Kjgtzv2QAhZBmWXoT7AdhTMGrlS2tjYuzSujTk44ziMevu38qRGVrhlGW2jPP8AStC5K+XtI+ZeAPUe9ULWEl2z1HOfWi4WJ44gAGRfn79qa0bOWRF+frg9/pVuNDsOeCRTrUpBdRSywJOF5MMmcP7HHNMTNqK7vV0XTI9L1jTLACM+dbzSIGMm4/OdynkjHHbFc34hnuE1bff3NteTlFBlhKlCMcAFQBkVqXeq2L8nw3pjyDncWk/LrzWFr0sF/KskFpFZjAHlQk7VI78880EWZ1Ns3yDnBrQt1MiTIDwU3Y9cc1j2j8qP4cVr6ecTIQSBnH4HiuBbntRFs5AsmOcE8VtQg4wAMng1gp+5nAxxmtu3PmkFTxjpnpTSOhaF62HlsDuHyngE449qewAkzESwGDnOMg+n41FtDsmR1yuR/KtAqv2MEgeaRiM+g9f6VaV0W5WGyACIQh+ANzMDwWFM/duTt3EMv3ahtMeUFZ+cgeuPwq2rDeUkba0nB45BHSkylpoTafHHNBcw3O5oZFwH7q38JI9O2ayYAISVYEEYwPXsfpWhFIFBYIQD8rAnsabcwxR3cbykSwuMvs7AjGR7g0rXsLumWVhRJCvK8hxIOSfbHpUyuWvHhkJkQ/uzIh4P+1/Ks0xl1KtMVZBtAfIJHb6VJJJvWKRGwSNrYGBkdP0q+awlE2oZAIVSUjy1lGcdVUjDY+vNP3Sw3Jt53Vdp2+YBu+XHBx34waoxbY0jlTJ4yit9ep9utTXFw8iozNygARQvzMpzhvfHI+lVcVibc7o8HVXOMMQvPc49MjpXP311IojjeJcqTyBjI9a0XmYk5ieTzT8jMuCeeCB6561namJIWj3RlRGerdWz6/rUt6XN6KsyXSrnbEY1mkWMncEUDkjpk9q0LG5SArMzN5oOUyoZTnrkH26ViW1zGyqkiEgYzsYDcPQ+9XWuIhIBDIZI8BiWXHPoR9e9XHYuUbluOfbKI1IMYOVI4I55q/O0cgzGf3mM/T2rAE37w4Cj6CrIuSsbMUDA8Fs4wa0TQnTuFxNLkg5OOCetQhmXBBO08Anr+VTRyMYWJ5J6k1Ulcqp2cj+VS0OK1saUA82PcDgDp2p9wg8pCAA3YismCaQNncdh6GtN5DJEGB4IxkdqaldCqJxKSS7Q6PwQe9TE4jxu6clqqOypMxc++aZNOsgBKkPnC4GBj396hslvsR6lIIrZ0JAOcYzwfc1iS8NGhbI2hsmrN+pluY0cOI1OSRz0qmg3zv1C54z1xWctTGUtbDZ3BIZjjHTHaqQfz7xEIDBPnIPf2q3dhY4ySfmJ61S0ps+fNjgnCnvikYTlrY2L+/muBHG4GMjaAMYHoPapZn/cLwAegrLjZpLkbf4ByT61JdSlIxk8dyKL3dyk9C5YRObISjcYg/luQOAT05961IZWTcrdR39RWHpz5iADEDO7bWyJWKqRgMvt1HpXRDYuDbRYJzllO7PPHOPakklDrhhgD0qEzIUHl5Ibpj+X1qOT5RiQtk87MdPqatlSZWuSXkxEQB/ESelTRoREywykFxhm7n2HoKpynL5Yg4+77VahmAjwQMisVFNmbY/aI0ClicdRVRSGy+Tk9Oc4FSTuGU+p6VThlURq542rkfXtTcNTOVRIRswysVBC5yy/1FRXmoJ5ZYvlBxxVO8vRhihyRnLep9KykIulkldiZNp+7/D/APXqlGxx1K9tgv8AVGG1ISPNc7mYjOAKgtftBuiRKpjIw6yDKyDuD7VBdR5m+QliSI+B+ZrXitgsIUIXUdN3QU0cspOW5VudMG7zIH2QN9xm4AHpnuR0pkrR2JwI/MZfuyPwuT7dT+NXJ1naymDMAi/Op6kev6fyrKkjEkjKxaWRvuIfT1NMkHMl7IOjogGfTPqRVqOFkQ7Tk5xnPJqext/suInOQeQfere0Bsuu4Y9KYGVdQ8gbSjnr7ioxCEAQEE7toPrxWpJbKWAYkE8nB6VTMJecxsxODlW9eKLARqSdoGd6nB9qWMxw3KvPGblFOXj3FNw9AR0qOZWjLKGJPvVdrkZIcHLDn3ouKx2WnaXBf2IubbwyxgcHazagV3YOCRntnvXKeL7QWGqNEbMWjKi5hWbzSpI7t6+3auj0yeOax09rqO6WOW2fS3KJlTk5Vk9WBIytZvi1Y5dTCRxzYgiSBmmXY7sgwWYdiabJS1KFlNlAQeldFanKKw7AVy5ja1vnjZSFJ+U9vpXQadJgAeorhZ60GXJVD5Y8EnirWnzmNR6A/nVdl3IQepp1hxIUb0zSTszp3OgthHM4bJCgFnP91R/nFXZG8/5m4GMBe2PSs6eH7PbLGpIlbDy+391f60+0kleL5mOE5X6d61utgSb1QI4gnYADZg5/+tWlbgPbxTkAsjBSQecjoay5UaMo6bj1yPQU+Gby+OTHuBGfbtSTRbuXXZIWfD7lOchhx19PSmXROC0fMJx06L7VZaaC7Ds2Srj5vLH3M9gPaqFy8gRo3HzrgcDHH0oasNO5p37z6hp8NwzWxmthtkAGJHX1PY4rLiucF404RiDg9jU8F1CqxfuonMZyd/O7/eqoxQzMwUYPIA4pTd9UVTWljThf5QCQV67SeKWa5YxiSNijLxgGs6K52uB1H5VKQQcq20Hnjmkn2KcSUyKLmIi54JHXP7s9z+fpWbdTNKBG5Pl7upzk1JKAsTExNjoGzVV2O1QUKjAByc8+vt9KLmtPchDBS6j7vqe1T20hOTnAHHpVNuB+vFTxvnbkDjg5FOOjN79C9LkTMNxYcHdjFNZ+cA7vx6VZWEmEsec1VlG1gdwHHP0rZqxKkW7a4IjCE47USkKhxVET7n4GQO/rSyOdrDI2nkVSehL7lnZtQSA0+1vhGjK/Qng1REr7flPy4wfSqp37do4X1rNu2wOzVmacxS4dQW4Aycd/SnRgiMFjkgkDHesmCQ72BI3dB+H/AOutOzcSRsjDBo0bOeV0jOmmKSTB13KVxgtjj198VVtWDkcnOM4qXWV8qMtxg/L9aqwnySD2xxUvsck5a3IdXmwuwHljtqvayeXB8uFXmquqSb7lFB5JLUkm4QiKAF2bgYpWOdy1uaOnvmN5OcscnNQ6pIywEA5LHAAp8KCKIKzDjsDwKrSx3GoXSQ2kZdhy2OijuSew9zSUWyueyNOzuE28qzMAPuitFhdCMzJakR44beDn29z7VVt2soEUqy3lwVwcf6lGH6t+g+tTwXcl0okuG3PkgjOAmD90AcCuiK6GtObHmZgG+zfuyfv7v9Y309Pw6+tJuYrnerLj0PNSSKki4Iz9apTLJGS0DAg9Vfv9D602rDcrBIwHJPSqL3PzYEmD9KS6u1AK8hwMkHtWRNdpGxdzk1mznnUN17pVTJk/MVmG682Fz8wtkbLMBgtnoq+pJrPgkkvZxGxG0+vQD+8fpTpJTK6wWsbeVFwgBxyerEeprRM5JzciO6SS4tDLJtgI+VUQ8jB6VYtoVht5NuXQDJbOM0lzHJGm/CPGv944LNTJ7xMKiqcOcyhhgLincysVreKaa8ihUNtTDuR3710JbCiMqwJ5I749hWXavwLlUJj3dUY5b3/+tWgryxAkRqjtyQrZYj69qEMZJ5vnRxP8qfxAc4H+17+1VpkCyIsQy3cg8gepNSu08pBWNkjXqQBwPX3q1bwxtGXTJVujdM09xCNbl4x5zcgZBIwRUaSozYZh8nvwT60syzzMYQfl6tI3XHpUgREQ70yB6imBG2Zck/KOme5qrcArdptbkLkccA9jViZPLUGN855INIinyyzkL5h545A9KQrETwiSLfIOeuBVFLVTKr8nJxjGa12j3RgKw2AYz3qu0ktq6TWshjliO5HHBH0osBrhbbUNM05HvzYy2kZiMbxO0bfMTvXb3Oefp1qh4mu0vLwNG0jKkUcIlkXDSlRjefc+9b9hfLYaZZmfXNQgWaHcttFCGCISRnOfxFQa/polSa4GpS38kSRNIZo9paNx8jKR1HamSc94otWCLcoPmjPPuO9RaVPvUD06V0l9GLhGjlX5mGMHvXG2Ia2uJIWOGRitcUj15LlkdSr5VcDNaGlRqryXUoBigxgf33P3V/qfYVlaej3LRxxDdLIdoH+e1a1zIgKW8B320PAb++38Tfj29sUorqaJ30RcB80FnJeRjluep9aks1MbgYG0np0qvY5B9MdeK0sK2CeR1BHpT3N9FoOkU8lX3Hpz0FVnhcNzt5Hep4w4TBLGP2HQH1p08OEKg7gOhBzTauCdiiDLaz7g2AecdRmlk3GUGRgFlAO4jOPapcZiKyKOeMnqKgaRGTYpYMO5qb2VirXYwq0Mx25KE9BWg5iMalNwA5IqlNKyxlSd34dagimYbgRj0oTSYF1SoO8cjvxTvOQn92TgfdBqk0+eVJpquQT8oB9Aad+xotS5LMzKQSdp55qjcEumzJ2g59zRKcxqcEOKglYAZY4PTOKVxxSQw7lViQD9aYlwPkOG4PP0pGY46Hjn6ClEQfC9N1UtdjVaq50sLJJbq245X1rP1D73ycjqB6VVsZXYeWpOQcN7VN0bLkEitm7ojZ3IzlUXaCPXNJO/yKeCPanvICpJ7VReTJIXkCoZhKoyWNySdp+UVBJKD1JBB/Oqkk7RzAD7jHn60u8b+Oh60nIUa3cl8wLcEA4zgj0rUtLgKMsfaseZAUJIyw5HvVmOcFAUAwepzyD7ihPUJTvoM8R3LboIxgAuD+VVJJWkORwBVPV7jzNTiV2ARYySaifzHVdxZUPfPLf4UnqzhqysyJyZLt9o3YOM9hUeoyeQ0YZjggnHqafaFUk2oME5/PNWL+3giii1C+RpRz5NuDjzT03MeyD9eg71SRzt9TStIY3gjub5zFA4yqry83sgPb1Y8fWszW9SeORI4V8mxJyYIzgN7sf4j9aqLqjz3q3F1IG8wBd2MKoHQAdh2A6UuuSwz2JVHUkkABep5prQd7mnp8xkiUbcMRlfce/vVp91vI1xECwP+sUfz+tZejtuhiGR8nQ+tbBm2Z5B9MVobQldFxLkPEGXkNyCDVO4mPXPHoKgzGk7BdyKwLDBxz3/AMaq3MrLuVCWI5OBmhu4SnZFa/nGMYyw54PSscM11IEVWkc5/Ct59PiWBGuWLySsDsQ5JHsKiOnM9s0kG/efux8bVHv70KJxyk5MS0tvI0rE4KzSZUxpzlc/3qjhuPKP2aCE+eSTtxyB6k0+2jdDGI5nkIypVhnBHakntPKnHmlFkJB2IDxk9T3/AAp7mdi1mfeilo0jDA5ADU28nUuudrxpzuVR83tj0rRe38yZfNXyoAuBGo+Zvr/hSKoZM+XiRjnHYAU7DKhGYB5T7Y3xlVAI59scUQK8rGMRkIO+cbhV0Wj3U8yKVjjbBZl6A/SrMIM0YSFNlwow3+yR1NNIZVtLVZhuCEqG5LcjjsBV2W2EZGwnzD0J6D8O1SW0ixwwxL7g59qmnDKxbG4EY9KqyFYzeRKV+VgU/Pmq92WiQovAPB5z+VXb2BktvMGI2j+YEn9Kp/Yt7xTSyMHUElD/AA/WlqDKaxqXC3G+Nj90lui0TGac+XEBKyjgnjI+tasFlkNNIMhv4fVafPar5YMajjlSvX6UWFYwoy+USdSGJwvOAD6VLM25fLmQq/r2P0q48azToQBJGi7nQ9QTwP61TvkCqFibev8AdJ+YfSk9BG3pEkUNlbLrUumGAgmzFxE7yBM99n8Gc4zUOs3t8k15azCAvMY5DNEvyyRgfu1X0QDoKitLm0ayt11Sznme3Xy0khlCMUySAwI7Z6il8QXDG8DyxxwIbeIwxI24JHj5Rn19aZHU17iKRQRIu5R/EOorifEcH2TUYrpTlJhhiPWvSpTIyY3DbjGMCs6+tIrW0F5NEr3Ay9tFgHDDOJSD2B6Dua5WrntVVoY0AOm2ohkBXUJl/eDvBGR93/eI6+gqeAL8oJ+Ud/Suc0O8a4d/tLF5mJLsxyWbuSfrXQ26NkNuJqHuTSfc1IC5CbDkAcZPWtCCTao3kgY64zj8KzrVtpC84JyPrV24X5mkjfY56ejf4VSRvcsRsBkqTk9z/npSbj5a7VIBORjsaqJOC37wbHXnB6VC14qEiMnGc5Hai5ViydodhklfWocES4kHYc+opkgkkjynDdRk4/nSFXkiG1kLDrlxwfrU2uJyS3I7ttzA7sY4qEEEEnkj0p5t5zE25UI77TuxVYnYpGUJx15pWYudEwfBJXIHQ1HscSErknHUGqouWViOnpmpRMwUbgcY5JoHGoWPPUgbuMfpUM5jcfK3FVxMrscjA9qhmmMZPQ+hp3ui3OxIflXAz+VSCdQg4BPselZoumkLBhkjvnrR5g3sTkHuKFKxXtGjTtLpUklXJBPzg5/OrL3A2llwc1gzE5SZGxtPP071Yec7ME8VakzN1ki6Z8g5IGexqLzD16g/rVRHYjhhTi4B+Zm44+UUbnPKpdj7hB5LFeo5qK3kEtqZEJJxxkY/SnqPMRtsoYdMHg/lVJHa1mZDG5Vs8kH5arlMXUSZcinLxgEcjrQ8nmRjygfNGMuDgD/Gq0EkRUB5o2HZQatxYdcIVI68Hilyj9pcyLxWXUVMjiV9mQSMAfhU/wA2VJVcD3ou4i94svlkRY2k46GnIhMwVFZmY4CjuaLamUpXI9Mth81xOM28BPmAdXY9EH1/lmm300l0ZLid0YnjHQKOygdgBV66hG7yFkKwQEllTnfIerf0HsKo3dqEcBIg0oHPOTj+lW0Zcxm2bblSB4mkXoPLUkn2q2loBIwNs8C5xiRSCPbNWW0y4VWmddoX5uZNu32Ap9qrMgaNpMkYPJI/HPFUiNSOzt8NxPGhTggnOf8ACnz3qR/LuTAbl1Of0qSCGK7i3yxMQG2k7FG8+2BS2ulm6lkdLcCJRgZkwOD1z3FDGm1sQfaJLmWNLYmQZJ3bfbnjrVmOW5toJG+wxl8YMgbDfgD1P0q0tp9lljMNuF64ffy/+771qWcUXmGSW3neY/dDnPT3/wAKaQ7t7nPqJpJ4WjQwNIDvJ+c4x+laa20ph8ksQnVSU2j/AAFXp9OSISXkJTzifMlQDg49O4OPzq8k6R7TISUKgjnPX3/xqkhcpzUlrHIzN5gjLLt4bPT8hViCO2tt4jUNI2AWY7j781Yv40nhZvkj5LbQMsaw4gst40SRtNIQNisePqaluzC1jRluDL5e08t3A6DpVtx5EbyyD5mXHTAHoBUVsiW3mBx5krd16D0A+lXBHJciOScKojcAqexz1qkIktonhhSEhTO3zOOoB96kht47eSVsk7iNzZ61qCFVU7ByevvWYoaa7c5xEpJPuelVsOxDbRoNQlVQMAeYPxqaeVZJNiDcqnn0B9CaiCtJqL7PuKgzj096s3qKtt5cQCk8AetF9AtcPLWWNN/zFmGPQfSqmo24kmxyGZcZHYZrRs0QmEg5UKTzTVCTXUr9lG0e9PdCsUlJiGJGYY754qoZJDIxhZRH/tVeuiUOcbsfKuO5qDbshbEeSASTjvSFYycgRvcIS3mOS6joMcCnRWsAnh89pEicjzPLALEe2amhjkW2iMcYCkDduPX3pEiPnRQM6maZgseWCjPpk9KQrF25/wCEfQFZZNWVh0O1Kw9emg1HUUltBKLdII4VMoG47BjnFb0mgXzSSRStZQlThka6TeD6Hniuev7F9NvGhLRF1AfbHIHXB9x3ouRZHpaRxxR/aJxuU9IiMGRh/wCyj1rL1Rnny0h3MT1x09h7VpXE5mcEsrKw4GNu046D2qmxR9yg8Zxz1rB9ke4u7PMruE2WuOEbaJPnA+tdNpx82E7s7/Tsaz/F9thknUcqdpPoD/8AXqzoszNbxmQAvEcZ749jUJHK3yyN9YVby22OCv31z+VSmRF3Bw209M84/HtUJmUsASV3jk85qC6cq3ykbv7xHUU2jaMriSxKHGZG4Hy59Kga4eMsM4GOSv8AU0+dpLiPaiPkcsThVX3zVJ4IMtvledOu1OAT7561DTKcx/2pnb9yQV/56E9fYU5xOTv4fv8AID/KoPtH2cMsUMcagnBI3HH41I97LKArzMB7HFLQm7JobneuRkMOhHBpJ5wykXA3An76cNn+tZ93L5ckcmfvqBIfXnAajzd2QR04xRewlK5YZGjj3q6ywE43gfoR2NVmdoiFz+6boM/dP+FOguGi+7hR0IIyGHuO9R35SS2eWDOFx5kfUx+/uvv270rXE5WEMmwsB19Kqz7pSSKZFI65YjcD/Oo7iVQcl8OfQ0rB7Sw9cxpgsd3rTBMy5JIx9apSTSbT+8yvQ8ZNVZJ2OAzgnptx0pqInWsa4ulY8ggehPWj7YggKEEkcdKy7aOe4kxBHI7gZIA6fX0qaS3lOCzrnOMKcqD9a1UWYTqocuqRxjb8wY8YJ/Wnx6qGGOcegHJqhcwiGaN7hR5RbaXzhf8AE1oWdiLlUeMEF+ioPlVR/Wq5TH2kpD4rq4Y7YERSRgbxnn8antodUYkuHljbqr4YfgKuCxkLj93EQOBxg5rYsUliQIyZkB4ReC3vVxQrGKtimwJ9kaB5OW2jcvvweRUlxZWdvFujD7MgNsbp9SOldTbxCPLXJUSNyc9FHoP8az7mONbjfphLz8tKkQzkZ6eme9VZBy2KCSpE8Sws7I2MiXgY/rVqwkRZJZwEAc7YgCMr/wDr7Vs2kNlq0KmC1hVn6lyBz3BHaq7eGrXy5EnLb1dkKCQ88+gFO3YbT6Gbf27SQxs/l+bvChFYYH19cVZ0/TgxDmQKi9+Mu3rVFvDYuZitoSY4x8wMhJwOmf8ACra6akeVuJoZH6Kiw/N7ACkCQ7V4Yoo1DkGVyBvY8ge1U4F8myJI8lHJKuwwAxPQ/wBKvWmjTYe4eVEkGfvLllA/2QakttLnuIU3TSSw7sxxcI0jd2PooJ70alWKyRMxit4oT5IXbu6fL/Ew+vQVoQJGGlQW5ZFI2A4xj+tTpp62KlUYTT4G6OcFix/2SOAPY1Jb28DNEfspBVMOrAKQxPpTSCxCAXvwWiYtFHk8dCTTJY5OfKRgx5IxwT/j71EyWlxPcmZTbxrJt8w5OcDoMH9aabe2L7oHluVHUpGSV9/ek9RosLd4ISUxJOBwHON1ZPnLbFk8xFcuxEO3cME/eB7/AErU/cPCyTySbDgq6RYH6iqohsluXa6iUsq5DqpOR64NFxNGdLcWoDx207SZx8uOCfpVOy0+aW6YGPaUOXEXXHpmtW4tjMqS7xGB9wQjIX8+9WbCzu1/eQ2wkfOS+dmfY59qVrsiw6C0it2VoW+8fkkzk/Q571aurSUxkkFmx8zIOo9cU59KubqMsrxwROMupcuwYdx0waLe1u4hH9o1GWQE7WDAKp/Ecg1dhp2FNz5untcIwEYX1wSaq2lu3lNHyrbOW9DjNJNsHl2yRlLXzfnY8gAHsfc1duCITIqMDEMFjnt9aA3K9ghRlIILOp3buuc9KjeX/SPLKk7RwRSiQz3CyxnYCDujJwSPX2p6GOWLCRSbSSSQOh9AaNw2IorghSIwQzHZjHT1NWIpVVGKAknocVBGDA8jy8HoCOgFR3UjFUFsw+bj6+9BIsCNcXPmOMRx8KPf1qxcER2chI/gP8qrBlt4thdpJTwFSoLqOeeJuRGowuByRk4x9aaBj4kxaRQqMvsGR6cd/wDCql1ZGaFYUQy3TttXaMsT6AVrx2cFvny1Oc8ljkms7VInTa1uWEgYbNg+bPbHvSa0EkMTTNYnm33NjdyShFTe0PLADAye59+tYurwXNleqs0LRMMFkddpwenFdbd6brV7meRfJuCAGRboKSwH3tu7gnuK5u5gufOnhvFkE6/Kyy53DH1qSUzr2t5ACQQfSoH82PLcn681orK2MOowPSopMbfmGM+lY2R7N+5zWtAXdvIh6sD+dc9p9w1su12CkDjd0/D1rr9QhAyce9cqQsFxMNkfy8gt296I76nJXVrNGxaaiGUNPhduMOx/QetWhdNenfbIvlr96R+cfRa59I0uphM7OVJxgD5iR2Hv7VNIZpmLWQZbdfuknauP8fendozUjUNwQGCmTjqCck/X/CoA4S3Ehxl325Htyf6VQ80FQGuIi2M7YgW/XpUt4+x0iRQ4iUA7jzk8nPr1/Ss2r6mqmkiZjuGSRhuxqt5mxguPpxTZruRdPjbCjMjghVxwMVmSXfmyZ+YE8YNS0NTua16NyQAgnMZGD9TVOOfICylgw4P1FQalcIiWfmyAMbcHOevJrKvdStkVTEuwgYdsk7j/AHsdqfLclzS3Nq4nBXOcAc+9U/7ReF/NV1Dr/e5B9j6g+lYY1TzC6FZHwpOSMdB61l3GozNLgKoXHBPp61cabMZ14o7DUbqFbdbyKYR2rnbtIJMcnUp+XIPcVz82rQysBB50rZwMAAE1T0iVhNcLdAmxmAScueFHZ1/2lPI/Ed6syMujXAtbYK90eDcEZJU8gqOgBB61r7NI53Xk9tCyq3e4eejx8Z2fxVqaXbF2LOvlpjLOx6fj/hVexhDRrPdEmAkldp5lPtnt71rwXMV4oDKqIvRB/D+P9aErCu3uSRMFjZIiPLU/MW/jPrt/xqvOQXQQI11ID91FyBn9PwpqW8jymS3C+VyRGzfeHerVneJCZUkbZMuPKGMAL6gdM80eo0QXGnXAEst4kQBGxUlfdjP+yO9O0Z5lCQbo4+2ZAdoxxjPUVrI0CWsruIjORyPMGVPv71HdNHKFmjZEjkVgdp53DGPp6U2irWLVqtwyk5MhDbVERGAxre0/TFMwL3EzSOvzkHB47Y7CqVuFeOKZFCSQ4JeIgFkI6474rft5P9Ig3snmYOyQcB/Yjt9PyqkjRFm20a2ZgZI/MI7tzT4bJUaZrUAl5NixjgNt4x7AckmrY1CGGye4Zgqxg7geobsv51Y0y3dbVXm+WcrlvSMHkj6nvT0KMB7J7O6mmikKBvmmOMgt0yPx4xViKK/iZ7aMQeY6fK5JJ3D7wI/HitKZoXmiaR41tydoXeMvn+I+1WVtwwMAKqIiMv6KOQfxyB+dANGAlk7orM4tnjz+7xkyL6k9x/KrlpEplE0cCIuNrPLxz/OtiaTdFuKpFNH1aTgA/wAyDXOXNyLuUyWzytbjKTyRrkqfRB068bj0zQ2CJLmd5ofs9msOAQJLgfKI8nP4n2q3ZQhEMDB4El6Ow+eb056D1xUGn2svmxxx2nlrEBKiSMMMCOC3qc5+lbCPNcRyCZLZEGd6yMWx7/8A16VwsNis0aJoHHyjhlAxn3NYc1s8E8s8TM9ov7v7QxyQo7e+D0NXp/t6OkjtE9pg7iQwYJ2Zx3A/P1qe4meeSKzW3MlsmHk+zkMrIOgPsTRcDMtLWHyUkit2mjI+WWQgZ+n/ANepmJO0rGxbtjhh+VaAs1dmls5Egx96OPJGf9oHp+FPmk6CWJo2H8QGR+YoKSMQTvBIWkh8y2dtrDOAjHvg+ves68tHvVMgQxgZ8tQPmUfX9a2L9Eu0+z+YAZSFRlx+v5VLZI08KNLK4l25YA9ex/WkNo5yG3nV42kJLg8KOPNX27Z9qvCdECm3MoHdWTlf8a15bOOMSIUMsOc4/iU+o/8ArVUnKQMDPIJLRhnzR96NvU+3v+dFrE2KslzPG7ZiARx94Zxu/wDrj+VV7qQwzqZhuRxwQcKDjnr7VfkGwJG/zKrgrIOjDtVDUrP+174wxyGK3gTdKx6M2ePrVCktNCoD5mnvcQRPHE8mcucKFB4AHf8A+vUH2Oe4uWkkChW/hU4ye3FagtrhBGJZlaFPuKRwcetRwB1G5kyXJbg/ypbiS7lW8s7qS1UlY90ZzwpViPr/AEpYruDMUMxNvO2Ao5Ct9K1fNjMJYEZPY+tYHiK588LBYwtMoBDvt+VeOoPrVMl6aktwdrYnbMW7JB6nFZtmTd37bI2EOf3eTtyO9QWsN1s32wnDsvzGRs8d+T0rSktpFs1mljeIRDcu053eoP1FJakN3LEMMk0ht4WjijQ5d0XJ9gCe9SXeYXgt8Zyd4OPT198kVYtZgiq7BBHKoKleg9sdqilbzdUTHIjiJJ9yf/rVQ0S7SQN3Wqz3X2C6hutnmCFw5XOMj+hq3nrzUMUsEepWj3IHkrIGfIzj3x3weaTG1oVILXSDE++8vIlZt+ya0+fB984P1qv4guhPco0CSKFhSJPN++yKMBm+tW3vX+0z2GtXgu7aTkXCHf5LHo6H09Vql4mlL38fkzRTRJaQx+bGcq2FwcVJC7HUu67cBCCTyT1xTGRW4Tp23f1qUBmkOeT6+tLLCVz3HQkCs7XPX2Mm9jIT07iuM1i0El4hYvtwfkUdW/wrvriMkZBHPGCa5TxLal7OQxjLAEgevtU2s7mFZXiYySETI8TxJsHBf5gv0A/nV+VFmYTyzLIkkZZYg2DnocZ6DNc7plylwUUHaqgk/wCyB2xWgLw3ljduQqyxMrcdArcEfmBTORSLcMkCXyRy2kcSAFmyTnAGfx6Vj39w24TqQyT5YE9Qc8g+4qfTJv8AR77zifLWPygWGSjPnkfgDTLCxYQyxSEF2O5M9N39Mj+lTy3Q+a2xHHFc3VtAq5jXcxJ79v8ACpjo6k/M8hUc5Jya0bJVljH73bt+XC8mtaytoN++QyeWnzMSTz7fjU36I1jDmV2ZF/pVv58UTpu8qGOMMehwOf1NVZNGiYlVjA+XiukmiOWmD7gxLHdyATSJtEjiUBSi859PUetF2aqkupyR0vySHIHlY3FvTjvVKTSAQrtGDEFyoxy3Pauv271Y4CxqSAMctz/niqjQrESmC6HuGwF9iP8ACmrmUoRORm0/7SoL7lRemenHQAVLcacxsod6jzLYBMSEndGeV3Y7A549xXRvagOGkGVblCnIH/16akUKu0Yc5kBRt3BIPt9cVakzCVJPU4175IXIDTySk4aSfC/gqjoPStK3vPKZUlD44JVRjHoSas3mnKxyiFZU4Dn19hTUtbuSJy8TBRy8snyqPxPWqvfYy5HEmV3viBLKY34CKoGSPUk062sWe7eKSMSeW2MryM/56irlpLb7YyXTOfmY9TVrSPIZJWj5laYhAh5x6mjcEtST7BaPEJIhEJEwXj27T7r9au2+mw3M8kSRSCMoChXHBPJ/SppIbgK8mEZSPm8wZJPY0W8awWv+kKfM+b5YvUHr7Ci5ryrqT2NnHDEplseEXL5H8PZhzyD3FTw3WkLM0Ly3sHHCpkn8OvFSQWcctvH5sziTb8nkE4H19fp0qW0tlV5op7GGMyLvRuoO3qBjp9KpDt2KUt9FLqECMt5IylWW4ZfvsDwdnsPXvXQR3ckXzatbvOjnC5mCp7blHH86ZPp6IsErSjyopFYrENvynrz19/wrds0W3YxmJZBtzjGSy92X+q/lQkXy23Io76R90VvZ2UcW3BO7p+grP017uPU3edsW1xtOIio2EAkY9MgE49a0tRjiihSK2dmEx2qqclV6nB/u4456VRktRe6jC90ieT5qDYBjoDgD296oTRZaa1vnR1trj7O52+dKpLTd9oJ6DrzWszWjEQgbLV0w67Cq9OB+VR30SRtZOrsqpMvAOcDaadA8sGnxyNmQM4YcYLZPAHrxQFiGxws8Ussq8qIBubqB0P51IjC/uWWPBt4j8rjne3qPUDt2qC7Xz4HglVRK7sFUDIiHr7nkDNOMQ+zpM8YjXAUQpxkjgD65pMpI0niO7yS5VG5kOcsw75PqaydJxp87WqJsgmzLAf7vqh+nGKuJbrHaTE5MpGWA6g+lLqCj7GjQ53rKrIR/L8qAtYdLEJJC4OydfuyAfofUe1NWbfuRwEmX7wHf3HtVuIK6K+fvDNVbuEyMPK/1y8qe34+1ItWKV2kZkiDqCpLEjHtVK0gVPOSJh+6kLKp/ukZxmrMai7nL42pH8mD/AHu9JDFm/nVcCPahPuRkYoKaQ9A9wf3aEIf4xJ/KmrpkTs7tEAW+XeznLD3q3Hu3yRqABnkj+EdwPepnwq4HAHGKZnY5S50eS1kLWs8hgA3NAG+7z/CT0+lH2dQSyXUpPVoiPm/EVrXchC3ATG7bjJ7cVWuoRDAgQN9pKhVfPzZ/wpg4orTRTyQEifbngfIDgVTvVa2jLSXI6YVUHLfhVhZ5I0SHKrKw+/8Awt/gaZ5KyTEkliOdx65NBLMu3g1C+US3Tgov3YlG1iPc96s2UUV7OzrJKqxjy/Lc8Z71qXK+VGkcQyxGABTRGkcQBZGxyTnvQTylKdyRFBtGXOxh2GP/AK1SPHulEYO63jHzL33H/CqxSQTSTKQTwyg89qvRqEiVmwSeScd6pMXL0MlbpLeNxIwMCHk+gNQ2CSGZ5AcebyM9BgdKg1qLzLo3KLm3xsmHY+9allGBG0DnLffVh/EPWluyUtQdp1yBGhHrmqjxzOuSuZZDtRF5Jz2q3I7F/Ib/AFv8x61PbSJDqUDStsjjBBf+4SCAfwzmgbMm/wBOjjVka/tY7kjZsIYqD6FwMD+VZdxBJZhrWZdkivtINdRcK0esWDs8qNCixG0SFmLDbgqpA2lW65J781ja6qPfwQhldooliYqcjcOuD3x0/CoZCfQ7VeYckAmmSEqCATj0ooqUeoQPhiysAdoJBxzWHqig5yPaiipkTI8lmQR3WomPKmNiBg9t3etHQyZGnR+VkhlVvfC5H6gUUU1ujze5Lp+G0qMkD95cybvfbHx/M1ahBF1HtYqGt/MIXpnFFFJjiTafM0jFyAJIxwy/KT9cVaOsXSPtyhUdAV6UUVnI6qLHXOrTrAXVYg2ByF68/WqNndzXV0BMwYnoSB8mPT0oopLY0qN81jc0q0S7tFe4Z3JYtjOAD9BVxIEiSV04KNsUcYAooqiorRMi+yQSwYeMfhxVOSwtmyrR5AIIyTRRQxSSsVtQU2Th4HcZbGCcgf1rM1ld5WR2d3Uggs2cUUUdTnmlYracom81pACQTgdq6LRUQtKuxcBlI49qKKvqYR3OhWONY5iEX5Iwwz6nvUGn2sTQajGwJEXQ55OfU96KK07Gj+I1JLOOCBjCzx5UFsN94+9Zov508mEkMm4H5hz1ooqHuaHS2SmSIo7MUIK468Zq3ArNpiSedIGTey4OMFeh/wAfWiitWIlihjTXtioBG1r5pXtuJ5NL5a3GoRxyZw07fMDhhhBjB/GiigCG7mka4FizEwpORn+IgKTgmtS3bzZIwwAEUEZQDtu4P6CiikieokWDq91kDhwPySmOx/tGRf4Y2WRR/tEc0UUxouSOwckHqMkY461npK32yKDjYkrY/wC+f/r0UUi0WbGVhZ44woYDj0JxT7hjHEgU4LkZPfmiihhEz2Ywy/u8AMSpH06H608HbcAL8pKhMjqBu6j3oopLYplm2jVVlA4AkIxQeetFFNiWxlRDfHED0JLn3IPes6aV3uZGJ+YEgH2oopsCO6ULbzLjI3K3Pv1qPS3LAIxyM7snr9KKKRMyWIecJppCWYHAHYUwqBAvA+c4PFFFUQthhjTzLk7QNiKBjjim6gvlKiozYLAYz60UUwI9RhT7MIsfIc5Hrwaz0mdbBGU4ZFBBoopEvcsxjN+sh5Yrim3hzHNn+9RRQBlXV3cpbPClxMsW7GwOQuPTFUbM5usdhwKKKzJe5//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_28_5572=[""].join("\n");
var outline_f5_28_5572=null;
var title_f5_28_5573="Glucocorticoid cellular effects";
var content_f5_28_5573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Cellular effects of glucocorticoids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_28_5573=[""].join("\n");
var outline_f5_28_5573=null;
var title_f5_28_5574="Tamoxifen: Patient drug information";
var content_f5_28_5574=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tamoxifen: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     see \"Tamoxifen: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/6/43111?source=see_link\">",
"     see \"Tamoxifen: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15512098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Soltamox&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F224658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Tamox&reg;;",
"     </li>",
"     <li>",
"      Mylan-Tamoxifen;",
"     </li>",
"     <li>",
"      Nolvadex&reg;-D;",
"     </li>",
"     <li>",
"      PMS-Tamoxifen;",
"     </li>",
"     <li>",
"      Teva-Tamoxifen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700778",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of a stroke or blood clots. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There may be a higher chance of endometrial or uterine cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691765",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat breast cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691587",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower the chance of breast cancer in women with a higher chance of getting it. It may lower the chance of getting cancer in the other breast after one has cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to cause egg release (ovulation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692146",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given to you for other reasons. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tamoxifen or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703722",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have blood clots or have had blood clots in the past.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had blood clots, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a bone density test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using OTC drugs, vitamins, natural products, or herbals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698553",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Periodic breast (monthly self-exam) and regular breast and gynecologic exams are major.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697828",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust during care and for 2 months after care ends.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4015123",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Period (menstrual) changes. Periods become less often or stop.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698101",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698382",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Uterine cancer may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698355",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stroke and blood clots may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4015124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cataracts may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4015143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad lower belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, period changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696379",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Only use the measuring device that comes with this liquid drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part not used after 3 months.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11068 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-543E46505B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_28_5574=[""].join("\n");
var outline_f5_28_5574=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15512098\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224658\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021572\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021574\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021573\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021578\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021579\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021581\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021576\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021577\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021582\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021583\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=related_link\">",
"      Tamoxifen: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/6/43111?source=related_link\">",
"      Tamoxifen: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_28_5575="ECG of atrial enlargement";
var content_f5_28_5575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Electrocardiograms showing atrial enlargement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    P wave morphology with atrial enlargement in leads I, II, and V1. The P waves in left atrial enlargement (left panel) are wide (&gt;0.12 sec) and notched in leads I and II and the terminal segment has a negative deflection that is deep and delayed in V1. In right atrial enlargement (middle panel), the P wave amplitude is increased (0.28 mV) in lead II. Biatrial enlargement (right panel) has characteristics of both atrial abnormalities: the P wave amplitude (0.22 mV) and duration (0.12 sec) are increased in lead II and there is deep terminal negativity in V1.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_28_5575=[""].join("\n");
var outline_f5_28_5575=null;
var title_f5_28_5576="Overview of primary prevention of coronary heart disease and stroke";
var content_f5_28_5576=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of primary prevention of coronary heart disease and stroke",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/28/5576/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/28/5576/contributors\">",
"     Charles H Hennekens, MD, DrPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/28/5576/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/28/5576/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/28/5576/contributors\">",
"     Freek Verheugt, MD, FACC, FESC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/28/5576/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/28/5576/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/28/5576/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States (US) and most developed countries, despite remarkable declines in mortality, cardiovascular disease (CVD), which includes coronary heart disease (CHD), stroke, and peripheral artery disease, remains far and away the leading cause of death [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5576/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the primary prevention of CVD is presented here, including a discussion of the additive benefits of risk factor reductions through therapeutic lifestyle changes and adjunctive drug therapies of proven benefit. Secondary prevention of CVD, emerging risk factors, and determining individual risk of a patient without known cardiovascular disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the US, since 1975, CVD mortality has declined by 24 to 28 percent overall, among men and women, as well as black and whites, although men and blacks continue to experience far higher mortality rates at earlier ages than their female and white counterparts, respectively. Further, the rate of decline has slowed since 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5576/abstract/2\">",
"     2",
"    </a>",
"    ]. It has been estimated that nearly half of the decline is due to earlier diagnosis and more aggressive treatment, particularly with medical therapies of life saving benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5576/abstract/3\">",
"     3",
"    </a>",
"    ]. The remaining half of the decline in CVD mortality is attributable to favorable changes in risk factors, such as the decline in cigarette smoking and aggressive management of blood pressure and lipids.",
"   </p>",
"   <p>",
"    The majority of known risk factors for CVD are modifiable by preventive measures, including therapeutic lifestyle changes and adjunctive drug therapies of proven benefit. In a descriptive study useful to formulate hypotheses, namely the worldwide INTERHEART study of patients from 52 countries, nine potentially modifiable factors accounted for over 90 percent of the population attributable risk of a first myocardial infarction (MI) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5576/abstract/4\">",
"     4",
"    </a>",
"    ]. These included cigarette smoking, dyslipidemia, hypertension, diabetes, abdominal obesity, and psychosocial factors. In addition, factors that improved the risk included daily consumption of fruits and vegetables, small amounts of daily alcohol consumption, and regular physical activity.",
"   </p>",
"   <p>",
"    The potential benefits of primary prevention strategies hypothesized from descriptive studies have been tested in analytic studies, including large prospective cohort studies. For example, in the Nurses' Health Study of over 120,000 female nurses followed for over 20 years, women who maintained a desirable body weight, ate a healthy diet, exercised regularly, and did not smoke cigarettes experienced an 84 percent reduction in their risk of clinical CVD events [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5576/abstract/5\">",
"     5",
"    </a>",
"    ]. The observation that only 3 to 5 percent of these dedicated and conscientious health professionals were in the lowest risk category reinforces the major clinical challenges in primary prevention. For lower risk women in the Women's Health Study of almost 40,000 female health professionals whose 10 year risk of a first CHD event was 2.5 percent, those practicing therapeutic lifestyle changes had a 55 percent lower risk of stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5576/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following major risk factors for CVD are modifiable and should be considered in all adults:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diet",
"     </li>",
"     <li>",
"      Smoking",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Dyslipidemia",
"     </li>",
"     <li>",
"      Physical inactivity",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Diabetes mellitus (considered in some guidelines as a CHD risk equivalent)",
"     </li>",
"     <li>",
"      Heavy Alcohol use",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of multiple risk factors confers at least additive risk. In Framingham, those with five risk factors had a 10 year risk of a first CHD event of 25 to 30 percent, which is comparable to the risk of many secondary prevention patients (",
"    <a class=\"graphic graphic_figure graphicRef55353 \" href=\"UTD.htm?24/31/25086\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5576/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, several large scale primary prevention trials and their meta-analyses demonstrate that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    reduces the risk of a first MI in apparently healthy individuals at low risk for a first event. We believe that any decision to use aspirin in primary prevention should be an individual clinical judgment that weighs the absolute risk of a first CHD event against the absolute risk of a major bleed. Nonetheless, aspirin is recommended for primary prevention of CHD by the United States Preventive Services Task Force (USPSTF) as an adjunct, not alternative to managing other risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5576/abstract/8\">",
"     8",
"    </a>",
"    ], as well as by the American Heart Association (AHA) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5576/abstract/9\">",
"     9",
"    </a>",
"    ], for apparently healthy men and women at moderate to high risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MAJOR COMPONENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Healthy diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals who consume a healthy diet have significantly lower risks of CVD, including both CHD and stroke. Components of a healthy diet include intakes of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fruits and vegetables",
"     </li>",
"     <li>",
"      Fiber, including cereals",
"     </li>",
"     <li>",
"      Foods with a low glycemic index and low glycemic load",
"     </li>",
"     <li>",
"      Monounsaturated fat rather than trans fatty acids or saturated fats",
"     </li>",
"     <li>",
"      Omega-3 fatty acids (from fish, plant sources, or supplements)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=see_link\">",
"     \"Healthy diet in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38649?source=see_link\">",
"     \"Dietary carbohydrates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2601?source=see_link\">",
"     \"Dietary fat\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link\">",
"     \"Fish oil and marine omega-3 fatty acids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observational studies have consistently shown that individuals consuming diets high in vegetables and fruits, such as the Mediterranean diet, have a reduced risk of CVD. It is possible that the apparent benefit may be due to specific compounds in vegetables and fruits, or to the fact that people who eat more vegetables and fruits tend to eat less meat and saturated fat. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=see_link&amp;anchor=H24#H24\">",
"     \"Healthy diet in adults\", section on 'Mediterranean diet'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Basic research has suggested mechanisms of benefit, and observational studies have shown that individuals who self-select for diets high in antioxidant vitamins or supplements have lower risks. Nonetheless, the most reliable data from large scale randomized trials have not shown significant benefits of antioxidant vitamin supplementation in the primary prevention of CVD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H18#H18\">",
"     \"Vitamin supplementation in disease prevention\", section on 'Antioxidant vitamins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking remains the leading avoidable cause of premature death and a major avoidable cause of premature disability. The totality of evidence indicates that the amount of cigarettes currently smoked increases morbidity and mortality from CVD, and benefits of cessation begin to appear after only a few months and reach that of the nonsmoker in several years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=see_link\">",
"     \"Cardiovascular risk of smoking and benefits of smoking cessation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All smokers should be counseled on a regular basis to quit. A number of approaches, including behavioral therapy, nicotine replacement therapy, and other pharmacologic therapies are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hypertension control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is a well-established risk factor for CVD, including morbidity and mortality from stroke, CHD, heart failure, and sudden death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37685?source=see_link\">",
"     \"Cardiovascular risks of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are a number of major issues related to hypertension in primary prevention of CVD, each of which is discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definition &mdash; Hypertension is generally defined as a systolic pressure &ge;140 mmHg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic pressure &ge;90 mmHg. However, patients with systolic 120 to 139 mmHg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic 80 to 89 mmHg have what has been termed prehypertension are also at increased cardiovascular risk. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=see_link&amp;anchor=H2#H2\">",
"       \"Hypertension: Who should be treated?\", section on 'Definitions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44677?source=see_link\">",
"       \"Prehypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Goal blood pressure &mdash; The goal blood pressure is usually &lt;140 systolic as well as &lt;90 mmHg diastolic, but higher risk patients have a lower goal, such as those with metabolic syndrome, diabetes, or proteinuric chronic kidney disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"       \"What is goal blood pressure in the treatment of hypertension?\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonpharmacologic measures &mdash; All patients with hypertension and prehypertension should practice nonpharmacologic therapeutic lifestyle changes, which include weight reduction, especially in",
"      <span class=\"nowrap\">",
"       overweight/obese",
"      </span>",
"      patients, salt restriction, and avoidance of excess alcohol intake. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=see_link&amp;anchor=H27#H27\">",
"       \"Overview of hypertension in adults\", section on 'Nonpharmacologic therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Choice of antihypertensive drug &mdash; Antihypertensive drugs are necessary for patients with persistent hypertension despite nonpharmacologic therapy. Most patients will require multiple antihypertensive drug therapies to achieve their blood pressure goal. In the absence of a specific indication (eg, beta blocker or calcium channel blocker for rate control in atrial fibrillation or angiotensin converting enzyme inhibitors in patient with diabetes), there are three main classes of drugs used for initial monotherapy: thiazide diuretics, angiotensin converting enzyme inhibitors or angiotensin receptor blockers, and long-acting dihydropyridine calcium channel blockers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"       \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dyslipidemia control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several large-scale randomized trials of statins in individuals without clinical evidence of CHD have demonstrated clinical benefits on CVD, including MI, stroke and CVD death as well as total mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5576/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deciding who should be screened for dyslipidemia may vary based on different guidelines. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33241?source=see_link\">",
"     \"Screening guidelines for dyslipidemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients, including those with dyslipidemia, should be counseled to exercise, eat a prudent diet, and lose weight as appropriate. Deciding when statin treatment should be initiated and the choice of adjunctive pharmacologic therapy of lipid disorders in primary prevention of CVD are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of observational studies have shown that individuals who self-select for increased physical activity have lower morbidity and mortality from CHD (",
"    <a class=\"graphic graphic_figure graphicRef81608 \" href=\"UTD.htm?28/55/29565\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Regular physical activity is recommended in the early school years and throughout life. Common recommendations include moderate intensity exercise for 150 minutes a week, vigorous intensity exercise for 75 minutes a week, or an equivalent combination of these activities. Adults with limited exercise capacity due to comorbidities should stay as physically active as their condition allows. Even modest amounts of regular physical activity such as brisk walking for 20 minutes daily are associated with significant benefits on risk of CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5576/abstract/11\">",
"     11",
"    </a>",
"    ]. The role of increased physical activity for primary prevention is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Weight loss",
"    </span>",
"   </p>",
"   <p>",
"    Obesity increases several major and modifiable risk factors for CVD, including hypertension, dyslipidemia, and insulin resistance as well as diabetes. Data from large prospective cohort studies have consistently shown that individuals with higher body weights have a linear increase in morbidity and mortality from CHD, after adjustment for other risk factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Selection of treatment for overweight subjects is based upon an initial risk assessment. All should be evaluated for their willingness and ability to adopt therapeutic lifestyle changes as well as other interventions of proven benefit. All individuals who are willing, ready, and able to lose weight should receive information about behavior modification, diet, and increased physical activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=see_link\">",
"     \"Screening for and clinical evaluation of obesity in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Glycemic control in diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morbidity and mortality from diabetes includes both macrovascular (CHD, stroke, and peripheral artery disease) as well as microvascular complications (retinopathy, nephropathy, and neuropathy).",
"   </p>",
"   <p>",
"    For macrovascular complications, intervention on multiple major risk factors is crucial, especially body weight, blood pressure, and lipids as adjuncts to glycemic control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link\">",
"     \"Overview of medical care in adults with diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For microvascular complications, tight glycemic control reduces microvascular complications in both type 1 and type 2 diabetes mellitus. Tight glycemic control may also reduce risks of macrovascular complications in patients with type 1 and type 2 diabetes mellitus. The target A1C levels in patients with diabetes should be tailored to the individual, by weighing the benefits on morbidity and mortality against the risk of hypoglycemia. Details of glycemic control in patients with diabetes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best predictor of future diabetes may be fasting triglycerides. Nonetheless, the American Diabetes Association (ADA) guidelines recommend that fasting blood glucose be performed in all individuals either at risk for diabetes or aged 45 years or older. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=see_link\">",
"     \"Screening for diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In primary prevention trials of individuals at low absolute risk of a first CHD event,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    confers a statistically-significant and clinically-important reduction in risk of a first MI, but the data on stroke and death from CVD remain inconclusive. Aspirin use for primary prevention of cardiovascular disease is discussed in detail separately, but the main conclusions will be reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision whether or not to recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in primary prevention should be based upon an individual clinical judgment that includes assessment of the magnitude of both the absolute CVD risk reduction and the absolute increase in risk of major bleeding. The Framingham risk score is commonly used for risk stratification in both men and women (",
"    <a class=\"graphic graphic_table graphicRef67655 graphicRef82417 \" href=\"UTD.htm?2/4/2112\">",
"     table 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For low-risk patients (ie, men and women whose 10 year absolute risk of a first coronary heart disease event is &lt;10 percent), the absolute benefit of a reduction in cardiovascular events is unlikely to exceed the absolute risk of major bleeding.",
"     </li>",
"     <li>",
"      For moderate- and high-risk patients (ie, men and women whose 10 year absolute risk of a first CHD event is &ge;10 percent), randomized data on benefits and risks are sparse. As a result, clinical decision making should be done on an individual basis for those individuals in whom the benefits of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      to prevent a first MI are likely to exceed the risk of major bleeding. An informed clinical decision should include whether to add aspirin to other preventive measures such as statins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;In numerous case-control and prospective cohort studies, individuals who consume small amounts of alcohol have lower risks of morbidity and mortality from CHD. The benefit seems related to the small amount of alcohol consumed rather than the type of alcoholic beverage. In some, but not the majority of analytic studies, individuals who consume red wine tend to have lower risks than those who consume other types of alcohol. This inconsistent finding may be due to other components in red wine or confounding by social class. For any individual, the difference between drinking small and larger amounts of alcohol may mean the difference between preventing and causing premature death. Specifically, any benefit of small daily alcohol intake must be weighed against increases in the risks which are apparent at greater than one drink daily. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38874?source=see_link\">",
"     \"Overview of the risks and benefits of alcohol consumption\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=see_link\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ADDITIVE BENEFITS OF RISK FACTOR REDUCTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In primary prevention, modification of multiple major risk factors will produce dramatic reductions in risk of CHD and stroke.",
"   </p>",
"   <p>",
"    A European prospective cohort study involving 1507 men and 832 women aged 70 to 90 without CVD or cancer at baseline assessed the individual and combined effects of self selection for a Mediterranean diet, being physically active, moderate alcohol use, and not smoking on all-cause and cause-specific mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5576/abstract/12\">",
"     12",
"    </a>",
"    ]. After a mean follow-up of 10 years, compared with those who adopted zero or one lifestyle change, those who self selected for all four therapeutic lifestyle changes had significantly lower risks of 67 percent for CVD mortality and 65 percent for total mortality.",
"   </p>",
"   <p>",
"    Similar results for primary prevention of stroke were seen in combined data from two large prospective cohorts, the Health Professionals Follow-up Study (43,685 men) and Nurses' Health Study (71,243 women), in which a low-risk lifestyle was defined as not smoking, BMI &lt;25",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    &ge;30 minutes per day of moderate activity, modest alcohol consumption, and scoring in the top 40 percent on a healthy diet score [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5576/abstract/13\">",
"     13",
"    </a>",
"    ]. Compared with participants having none, men and women with all five low-risk factors had significantly lower risks of stroke (relative risks 0.31 in men and 0.21 in women).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Polypill",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of a \"polypill,\" or combination of medications to reduce CVD, has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5576/abstract/14\">",
"     14",
"    </a>",
"    ], which includes individual components that favorably affect lipids and blood pressure, for which there is conclusive evidence of benefits. It also, however, includes other agents such as ACE inhibitors, which may not benefit all primary prevention subjects as well as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    to reduce homocysteine, for which randomized trials have not supported benefits on clinical CVD outcomes that had been suggested by basic research and observational epidemiologic studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At present, even in secondary prevention, virtually all patients would benefit from statins and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , a subset would benefit from blood pressure lowering, and perhaps none from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    to reduce homocysteine. The polypill is currently a research, not clinical, challenge and requires cogent data from randomized trials of sufficient size, dose, duration, using a factorial design and accruing an adequate number of clinical endpoints prior to widespread use in either secondary or primary prevention of CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5576/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/5/23635?source=see_link\">",
"       \"Patient information: Atherosclerosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"       \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=see_link\">",
"       \"Patient information: Diet and health (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       \"Patient information: Quitting smoking (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"       \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/54/40803?source=see_link\">",
"       \"Patient information: Aspirin and cardiovascular disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"       \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following major risk factors for cardiovascular disease (CVD) are modifiable and should be considered in all adults: poor diet, smoking, hypertension, dyslipidemia, physical inactivity, obesity, diabetes mellitus, and heavy alcohol use. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=see_link\">",
"       \"Healthy diet in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=see_link\">",
"       \"Hypertension: Who should be treated?\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link\">",
"       \"Exercise and fitness in the prevention of cardiovascular disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"       \"Overview of therapy for obesity in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link\">",
"       \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"       \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=see_link\">",
"       \"Cardiovascular benefits and risks of moderate alcohol consumption\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The decision to recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      is based upon an individual clinical judgment that includes an assessment of the magnitude of both the absolute CVD risk reduction and the absolute increase in major bleeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"       \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"       \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Modification of multiple risk factors, through therapeutic lifestyle changes and adjunctive drug therapies of proven benefit, is likely to have at least additive benefits in the primary prevention of CVD. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Additive benefits of risk factor reductions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5576/abstract/1\">",
"      Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5576/abstract/2\">",
"      Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999; 81:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5576/abstract/3\">",
"      Capewell S, Beaglehole R, Seddon M, McMurray J. Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, between 1982 and 1993. Circulation 2000; 102:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5576/abstract/4\">",
"      Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5576/abstract/5\">",
"      Stampfer MJ, Hu FB, Manson JE, et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000; 343:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5576/abstract/6\">",
"      Kurth T, Moore SC, Gaziano JM, et al. Healthy lifestyle and the risk of stroke in women. Arch Intern Med 2006; 166:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5576/abstract/7\">",
"      Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005; 365:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5576/abstract/8\">",
"      Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5576/abstract/9\">",
"      Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5576/abstract/10\">",
"      Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5576/abstract/11\">",
"      Manson JE, Hu FB, Rich-Edwards JW, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999; 341:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5576/abstract/12\">",
"      Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA 2004; 292:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5576/abstract/13\">",
"      Chiuve SE, Rexrode KM, Spiegelman D, et al. Primary prevention of stroke by healthy lifestyle. Circulation 2008; 118:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5576/abstract/14\">",
"      Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5576/abstract/15\">",
"      Lonn E, Bosch J, Teo KK, et al. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation 2010; 122:2078.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7573 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-7705E05A5A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_28_5576=[""].join("\n");
var outline_f5_28_5576=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MAJOR COMPONENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Healthy diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hypertension control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dyslipidemia control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physical activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Glycemic control in diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Alcohol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ADDITIVE BENEFITS OF RISK FACTOR REDUCTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Polypill",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/7573\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7573|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/31/25086\" title=\"figure 1\">",
"      Number of risk factors and CVD risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/55/29565\" title=\"figure 2\">",
"      Exercise and cardiac events",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7573|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/37/18014\" title=\"table 1A\">",
"      Framingham risk score men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/40/19086\" title=\"table 1B\">",
"      Framingham risk score women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=related_link\">",
"      Cardiovascular risk of smoking and benefits of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37685?source=related_link\">",
"      Cardiovascular risks of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38649?source=related_link\">",
"      Dietary carbohydrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2601?source=related_link\">",
"      Dietary fat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=related_link\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=related_link\">",
"      Healthy diet in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38874?source=related_link\">",
"      Overview of the risks and benefits of alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/54/40803?source=related_link\">",
"      Patient information: Aspirin and cardiovascular disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/5/23635?source=related_link\">",
"      Patient information: Atherosclerosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=related_link\">",
"      Patient information: Diet and health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=related_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44677?source=related_link\">",
"      Prehypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=related_link\">",
"      Screening for and clinical evaluation of obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=related_link\">",
"      Screening for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33241?source=related_link\">",
"      Screening guidelines for dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=related_link\">",
"      Secondhand smoke exposure: Effects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_28_5577="Trypanosoma cruzi life cycle";
var content_f5_28_5577=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 630px\">",
"   <div class=\"ttl\">",
"    Life cycle of",
"    <em>",
"     Trypanosoma cruzi",
"    </em>",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 610px; height: 475px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An infected triatomine insect vector (or \"kissing\" bug) takes a blood meal and releases trypomastigotes in its feces near the site of the bite wound. Trypomastigotes enter the host through the wound or through intact mucosal membranes, such as the conjunctiva (1). Common triatomine vector species for trypanosomiasis belong to the genera",
"    <em>",
"     Triatoma, Phodinius,",
"    </em>",
"    and",
"    <em>",
"     Panstrongylus",
"    </em>",
"    . Inside the host, the trypomastigotes invade cells near the site of inoculation, where they differentiate into intracellular amastigotes (2). The amastigotes multiply by binary fission (3) and differentiate into trypomastigotes, and then are released into the circulation as bloodstream trypomastigotes (4). Trypomastigotes infect cells from a variety of tissues and transform into intracellular amastigotes in new infection sites. Clinical manifestations can result from this infective cycle. The bloodstream trypomastigotes do not replicate (different from the African trypanosomes). Replication resumes only when the parasites enter another cell or are ingested by another vector. The \"kissing\" bug becomes infected by feeding on human or animal blood that contains circulating parasites (5). The ingested trypomastigotes transform into epimastigotes in the vector's midgut (6). The parasites multiply and differentiate in the midgut (7) and differentiate into infective metacyclic trypomastigotes in the hindgut (8).",
"    <em>",
"     Trypanosoma cruzi",
"    </em>",
"    can also be transmitted through blood transfusions, organ transplantation, transplacentally, and in laboratory accidents.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention.",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/trypanosomiasisamerican.htm\">",
"      file://www.dpd.cdc.gov/dpdx/html/trypanosomiasisamerican.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_28_5577=[""].join("\n");
var outline_f5_28_5577=null;
var title_f5_28_5578="Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects";
var content_f5_28_5578=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/28/5578/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/28/5578/contributors\">",
"     Michael Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/28/5578/contributors\">",
"     Robert J Birnbaum, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/28/5578/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/28/5578/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/28/5578/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/28/5578/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/28/5578/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in understanding brain neurophysiology have led to the development of &ldquo;dual action&rdquo; antidepressants called serotonin-norepinephrine reuptake inhibitors (SNRIs), but have little or no effect upon cholinergic, or histaminergic receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/1\">",
"     1",
"    </a>",
"    ]. SNRIs include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"       Desvenlafaxine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       Duloxetine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"       Milnacipran",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       Venlafaxine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Indications for these drugs include depressed patients with poor responses or intolerable side effects during first-line treatment with selective serotonin reuptake inhibitors (SSRIs) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, clinicians use SNRIs to treat panic disorder, generalized anxiety disorder, social anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder, and body dysmorphic disorder. SNRIs are also beneficial for painful diabetic peripheral neuropathy, fibromyalgia, menopausal hot flashes, vulvodynia, and urinary incontinence. See appropriate topic reviews.",
"   </p>",
"   <p>",
"    The pharmacology, administration, and side effects of SNRIs are reviewed here. Choosing a regimen for the initial treatment of major depression and treatment of resistant depression is discussed separately, as are other antidepressant drug classes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link\">",
"       \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5129?source=see_link\">",
"       \"Serotonin modulators: Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5417?source=see_link\">",
"       \"Atypical antidepressants: Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link\">",
"       \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7574?source=see_link\">",
"       \"Monoamine oxidase inhibitors (MAOIs) for treating depressed adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2256741\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87088683\">",
"    <span class=\"h2\">",
"     Structure",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"     Desvenlafaxine",
"    </a>",
"    (also called O-desmethylvenlafaxine) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    are bicyclic phenylethylamine compounds with similar structures (removal of a methyl group from venlafaxine results in the active metabolite desvenlafaxine) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     Duloxetine",
"    </a>",
"    is naphthalene compound and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    is a phenylethylamine compound [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/5\">",
"     5",
"    </a>",
"    ]; their structures are dissimilar from each other and from desvenlafaxine and venlafaxine [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2257250\">",
"    <span class=\"h2\">",
"     Pharmacodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serotonin-norepinephrine reuptake inhibitors (SNRIs) appear to treat depression by initially blocking presynaptic serotonin and norepinephrine transporter proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. This inhibits reuptake of these neurotransmitters and leads to increased stimulation of post-synaptic receptors. However, the SNRIs vary in their affinity for the serotonin transporter and norepinephrine transporter.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"     Desvenlafaxine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    are more potent inhibitors of serotonin reuptake than norepinephrine reuptake, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    blocks reuptake of norepinephrine more preferentially. For each drug, the approximate ratio for inhibition of serotonin versus norepinephrine reuptake in vitro is [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"       Desvenlafaxine",
"      </a>",
"      11:1",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       Duloxetine",
"      </a>",
"      5:1",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"       Milnacipran",
"      </a>",
"      1:2 &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       Venlafaxine",
"      </a>",
"      10:1 &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many authorities regard",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    as essentially a selective serotonin reuptake inhibitor at lower doses (eg, &le;150 mg per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. As the dose increases, venlafaxine blocks norepinephrine reuptake more potently.",
"   </p>",
"   <p>",
"    Although SNRIs rapidly inhibit serotonin and norepinephrine reuptake transporters in the brain, therapeutic effects are generally delayed for weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/6\">",
"     6",
"    </a>",
"    ]. The delay may be due to activation of neuronal autoreceptors that initially suppress firing of the neurons; this activation is concurrent with reuptake inhibition. After a few weeks of administering the drug, the autoreceptors become desensitized, which then leads to a net increase in neurotransmission. &nbsp;",
"   </p>",
"   <p>",
"    SNRIs can be used to treat neuropathic pain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/7\">",
"     7",
"    </a>",
"    ]. Increased noradrenergic neurotransmission induced by SNRIs is thought to inhibit spinal cord pain pathways and suppress pain. Treatment of chronic pain with SNRIs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link&amp;anchor=H9187603#H9187603\">",
"     \"Overview of the treatment of chronic pain\", section on 'Serotonin norepinephrine reuptake inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The SNRIs have little or no effect upon dopaminergic, cholinergic, histaminergic, or alpha1-adrenergic receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/1\">",
"     1",
"    </a>",
"    ]. However, these drugs stimulate norepinephrine receptors in the sympathetic nervous system, which leads to a relative decrease in parasympathetic tone; this can cause &ldquo;pseudoanticholinergic&rdquo; side effects (eg, constipation, dry mouth, and urinary retention), despite the lack of direct effects upon cholinergic receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276509802\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacokinetic parameters of SNRIs vary (",
"    <a class=\"graphic graphic_table graphicRef88063 \" href=\"UTD.htm?14/7/14461\">",
"     table 1",
"    </a>",
"    ). Food decreases the rate but not the degree of absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/4\">",
"     4",
"    </a>",
"    ]; administering the drugs with food may reduce nausea, which is generally the most common side effect of SNRIs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276509825\">",
"    <span class=\"h3\">",
"     Drug-drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     Duloxetine",
"    </a>",
"    is a moderately potent inhibitor of the hepatic cytochrome P450 enzyme CYP2D6, and may thus interact with other drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. By contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"     desvenlafaxine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    do not potently or moderately inhibit P450 enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/7,14,15\">",
"     7,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SNRIs are contraindicated in patients who received monoamine oxidase inhibitors (MAOIs) in the previous two weeks because of drug-drug interactions that cause the serotonin syndrome. In addition, SNRIs should be used cautiously with other serotonergic drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , selective serotonin reuptake inhibitors, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef64604 \" href=\"UTD.htm?42/19/43324\">",
"     table 2",
"    </a>",
"    ). Specific interactions of SNRIs with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions. The serotonin syndrome is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276509607\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276509615\">",
"    <span class=\"h2\">",
"     Guidelines to review with patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to prescribing SNRIs, clinicians should discuss:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Drug interactions",
"     </li>",
"     <li>",
"      Side effects",
"     </li>",
"     <li>",
"      Time to response",
"     </li>",
"     <li>",
"      Stopping the medication",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Common and serious side effects (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"     table 3",
"    </a>",
"    ) and the need to take the medication as prescribed rather than on an as needed basis should be reviewed. Patients should also be informed that although some response may occur within the first two weeks of treatment, it may take many weeks (eg, 8 to 14) for a full response (severity of illness and co-morbid disease may affect how quickly depressed patients respond to treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, clinicians should caution patients to not abruptly discontinue antidepressants, which may precipitate dysphoria, dizziness, gastrointestinal distress, fatigue, chills, and myalgias [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/17\">",
"     17",
"    </a>",
"    ]. This discontinuation syndrome appears to be particularly common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    and relatively uncommon with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    . Additional information about the discontinuation syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link&amp;anchor=H12#H12\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\", section on 'Discontinuation of antidepressants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276509622\">",
"    <span class=\"h2\">",
"     Medical tests and plasma levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific medical tests are required before starting SNRIs, and drug serum concentrations are not routinely monitored because they have not been shown to correlate with clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/18\">",
"     18",
"    </a>",
"    ]. However, levels can assess adherence and whether unresponsive patients are rapid metabolizers. Levels can also establish that it is safe to begin another serotonergic drug (eg, a selective serotonin reuptake inhibitor or monoamine oxidase inhibitor) after discontinuing an SNRI, in order to avoid the serotonin syndrome (",
"    <a class=\"graphic graphic_table graphicRef64604 \" href=\"UTD.htm?42/19/43324\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276509636\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest starting SNRIs with the lowest minimal effective dose in order to avoid side effects and slowly increasing the dose in unresponsive patients. Starting doses and target dose ranges of each SNRI are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef88068 \" href=\"UTD.htm?30/41/31388\">",
"     table 4",
"    </a>",
"    ). Depressed patients with comorbid anxiety disorders may tolerate the medication better by starting with half of the suggested dose. Doses are adjusted according to patient response, tolerability, and clinical urgency.",
"   </p>",
"   <p>",
"    Finding the effective dose of an antidepressant involves trial and error. After starting the antidepressant and titrating up to the minimum effective dose, response should be monitored over the next two to four weeks. For patients who tolerate the drug but do not respond, we continue titrating up the dose slowly (to avoid side effects such as nausea) every two to four weeks. For unresponsive patients who do not tolerate the drug, we suggest switching to a different antidepressant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who recover from an episode of major depression should generally receive maintenance treatment with the full dose that successfully resolved the episode, rather than a lower dose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/39/9850?source=see_link&amp;anchor=H8038660#H8038660\">",
"     \"Unipolar depression in adults: Continuation and maintenance treatment\", section on 'Dose'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85891991\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administering SNRIs with food may reduce nausea, which is the most common side effect [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extended release tablets (which are available for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"     desvenlafaxine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ) and capsules (venlafaxine) are intended to be swallowed whole and not divided, crushed, or chewed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/19\">",
"     19",
"    </a>",
"    ]. However, venlafaxine extended release capsules can be opened and the pellets can be sprinkled on food (eg applesauce), which should be swallowed immediately without chewing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18324389\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects that are common to SNRIs include (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nausea",
"     </li>",
"     <li>",
"      Dizziness",
"     </li>",
"     <li>",
"      Diaphoresis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of these and other side effects for each drug are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85891871\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of pregnant women with antidepressants is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link\">",
"     \"Depression in pregnant women: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85892292\">",
"    <span class=\"h2\">",
"     Suicide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential effect of SNRIs on suicidal ideation and behavior in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43783?source=see_link\">",
"     \"Effect of antidepressants on suicide risk in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DESVENLAFAXINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"     desvenlafaxine",
"    </a>",
"    for unipolar major depression is 50 mg once daily (",
"    <a class=\"graphic graphic_table graphicRef88068 \" href=\"UTD.htm?30/41/31388\">",
"     table 4",
"    </a>",
"    ). For patients who do not respond after two to four weeks, the dose is increased to 100 mg once daily. For patients who remain depressed after two to four weeks, the dose is increased further by increments of 50 mg per day every two to four weeks, to a maximum of 400 mg once daily. In clinically urgent situations (eg, during inpatient treatment), dose increases of 50 mg per day can occur as quickly as every seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/20\">",
"     20",
"    </a>",
"    ]. Although doses up to 400 mg per day have been studied and may be useful, there are no data that indicate doses &gt;50 mg per day provide any additional benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. For patients with severe renal impairment (creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/minute)",
"    </span>",
"    or end-stage renal disease, the recommended dose is 50 mg every other day [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/23\">",
"     23",
"    </a>",
"    ]. For patients with hepatic impairment, the dose is limited to 100 mg per day.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"     Desvenlafaxine",
"    </a>",
"    50 mg per day is generally well tolerated (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"     table 3",
"    </a>",
"    ). Adverse effects that occurred in randomized trials (N = 953 patients with major depression) at least twice as often with desvenlafaxine than placebo included [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nausea &ndash; 22 percent of patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"       desvenlafaxine",
"      </a>",
"     </li>",
"     <li>",
"      Dizziness &ndash; 13 percent",
"     </li>",
"     <li>",
"      Sweating &ndash; 10 percent",
"     </li>",
"     <li>",
"      Constipation &ndash; 9 percent",
"     </li>",
"     <li>",
"      Anorexia &ndash; 5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the mean weight loss over eight weeks with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"     desvenlafaxine",
"    </a>",
"    50 mg per day was approximately 0.4 kg, and with desvenlafaxine 100 mg per day was approximately 0.4 to 0.9 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/20,21,24\">",
"     20,21,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood pressure may increase in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"     desvenlafaxine",
"    </a>",
"    and should thus be checked at baseline and regularly thereafter (eg, every two to six months). In randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"       Desvenlafaxine",
"      </a>",
"      50 mg per day (N = 149 patients with unipolar major depression) caused a mean increase in supine systolic blood pressure of 2 mmHg, and diastolic pressure 1 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"       Desvenlafaxine",
"      </a>",
"      100 mg per day (N = 109, 145, and 110 patients with unipolar major depression) caused a mean increase in supine systolic blood pressure of 2 to 4 mmHg, and diastolic pressure 1 to 2 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/20,21,24\">",
"       20,21,24",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of intolerable side effects secondary to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"     desvenlafaxine",
"    </a>",
"    appears to be correlated with the dose [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/20,21,23\">",
"     20,21,23",
"    </a>",
"    ]. A pooled analysis of nine randomized trials (1834 patients with unipolar major depression) found that discontinuation of treatment due to adverse effects occurred as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Placebo &ndash; 3 percent of patients",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"       Desvenlafaxine",
"      </a>",
"      50 mg per day &ndash; 4 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"       Desvenlafaxine",
"      </a>",
"      100 mg per day &ndash; 8 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"       Desvenlafaxine",
"      </a>",
"      200 mg per day &ndash; 14 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"       Desvenlafaxine",
"      </a>",
"      400 mg per day &ndash; 18 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nausea is the most common reason for discontinuing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"     desvenlafaxine",
"    </a>",
"    , and occurs most frequently during the first week of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abrupt discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"     desvenlafaxine",
"    </a>",
"    50 mg per day may cause symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/23\">",
"     23",
"    </a>",
"    ], but they do not appear to be pronounced [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/19\">",
"     19",
"    </a>",
"    ]. For patients treated with higher doses who decide to stop the medication, we suggest tapering the drug over two to four weeks to reduce the risk of withdrawal symptoms (such as dizziness, nausea, headache, irritability, insomnia, and diarrhea) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/10,25\">",
"     10,25",
"    </a>",
"    ]. In a pooled analysis of 10 randomized trials (N = 1724 patients with unipolar major depression) that compared desvenlafaxine (50 to 400 mg per day) with placebo for eight weeks, discontinuation symptoms in desvenlafaxine- and placebo-treated patients occurred in 40 and 27 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/25\">",
"     25",
"    </a>",
"    ]. However, the discontinuation syndrome occurred in only six patients who abruptly stopped desvenlafaxine 100 mg per day without a taper (patients treated with higher doses were tapered prior to stopping the drug). The discontinuation syndrome is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link&amp;anchor=H12#H12\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\", section on 'Discontinuation of antidepressants'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DULOXETINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     Duloxetine",
"    </a>",
"    is contraindicated in patients with uncontrolled angle-closure (narrow angle) glaucoma; is generally avoided in patients with severe renal impairment (creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/minute),",
"    </span>",
"    end-stage renal disease, or hepatic impairment; and should be used cautiously in patients with chronic liver disease or alcohol abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with major depression, we typically start",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    at a dose of 30 mg daily to minimize side effects and usually increase the dose to 60 mg daily after one week. However, it is reasonable to start at 60 mg once per day, or with 20 to 30 mg twice per day [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/27\">",
"     27",
"    </a>",
"    ]. For patients who do not respond to 40 to 60 mg per day after two to four weeks, the dose can be titrated up by 30 mg per week every one to four weeks, to a maximum of 120 mg per day (either as a single daily dose or given as 60 mg twice per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/7\">",
"     7",
"    </a>",
"    ]. However, there is no evidence that doses &gt;60 mg per day provide any additional benefit. As an example, an eight week randomized trial compared duloxetine 60 mg per day with duloxetine 120 mg per day in 336 patients with severe major depression and found that remission was comparable (51 and 55 percent of patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/28\">",
"     28",
"    </a>",
"    ]. Although therapeutic drug monitoring of serum concentrations may be useful in determining the optimal dose [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/29\">",
"     29",
"    </a>",
"    ], this is not standard clinical practice.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     Duloxetine",
"    </a>",
"    can cause several side effects (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"     table 3",
"    </a>",
"    ). A pooled analysis examined adverse effects in eight randomized trials that compared duloxetine (40 to 120 mg per day) with placebo for eight or nine weeks in 1916 patients with unipolar major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/30\">",
"     30",
"    </a>",
"    ]. Discontinuation of treatment due to side effects was greater in patients who received duloxetine than placebo (10 versus 4 percent). Adverse effects that occurred more frequently with duloxetine than placebo included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nausea &ndash; 20 percent of patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"     </li>",
"     <li>",
"      Dry mouth &ndash; 15 percent",
"     </li>",
"     <li>",
"      Constipation &ndash; 11 percent",
"     </li>",
"     <li>",
"      Insomnia &ndash; 10 percent",
"     </li>",
"     <li>",
"      Dizziness &ndash; 9 percent",
"     </li>",
"     <li>",
"      Fatigue &ndash; 8 percent",
"     </li>",
"     <li>",
"      Diarrhea &ndash; 8 percent",
"     </li>",
"     <li>",
"      Somnolence &ndash; 7 percent",
"     </li>",
"     <li>",
"      Diaphoresis &ndash; 6 percent",
"     </li>",
"     <li>",
"      Anorexia &ndash; 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other side effects that occurred with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    included [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight change &ndash; Weight loss with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      during treatment lasting 8 to 9 weeks was 0.5 kg; however, in studies lasting up to 34 weeks, weight gain &ge;7 percent of baseline weight with duloxetine 80 mg per day occurred in 9 percent of patients, and with 120 mg per day in 13 percent",
"     </li>",
"     <li>",
"      Sexual dysfunction &ndash; Among patients without sexual dysfunction at baseline, sexual impairment was greater with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      than placebo (46 versus 29 percent of patients).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By contrast, blood pressure changes with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    were negligible; the mean increase in supine systolic and diastolic pressure were each &lt;1 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects were also studied in a pooled analysis of nearly 24,000 patients who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    for treatment of unipolar major depression, lower urinary tract disorders, diabetic peripheral neuropathic pain, or generalized anxiety disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/31\">",
"     31",
"    </a>",
"    ]. Discontinuation of treatment due to side effects occurred in 20 percent of the patients.",
"   </p>",
"   <p>",
"    For patients who discontinue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    , we suggest tapering the dose over two to four weeks to reduce discontinuation emergent adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/10,32\">",
"     10,32",
"    </a>",
"    ]. A pooled analysis examined discontinuation symptoms after treatment was stopped abruptly in six randomized trials that compared duloxetine (40 to 120 mg per day) with placebo for eight or nine weeks in 870 patients with unipolar major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/32\">",
"     32",
"    </a>",
"    ]. Discontinuation symptoms occurred in more patients who received duloxetine than placebo (44 versus 23 percent). Symptoms that occurred more often with duloxetine than placebo included dizziness, nausea, and headache. The discontinuation syndrome is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link&amp;anchor=H12#H12\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\", section on 'Discontinuation of antidepressants'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    has been marketed as a uniquely beneficial treatment for physical pain associated with depression, none of the trials that studied this outcome included an active control [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/33\">",
"     33",
"    </a>",
"    ]. A systematic review concluded that duloxetine was beneficial for pain caused by fibromyalgia and diabetic neuropathy, but the effectiveness of duloxetine appeared to be comparable to that of other antidepressants (eg, tricyclics) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MILNACIPRAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     Milnacipran",
"    </a>",
"    is contraindicated in patients with uncontrolled angle-closure (narrow angle) glaucoma, generally avoided in patients with end-stage renal disease, and should be used cautiously in patients with chronic liver disease or alcohol abuse due to reports of increased liver enzymes and hepatic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/10,26\">",
"     10,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    for major depression is 12.5 mg once per day, which is titrated up to 12.5 mg twice daily on day two or three of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/12\">",
"     12",
"    </a>",
"    ]. In the absence of significant side effects, the dose is increased to 50 mg twice daily by day seven of treatment. For patients who do not respond after two to four weeks and are tolerating the drug, the dose can be increased up to 100 mg twice daily. After steady state serum concentrations have been achieved (in approximately two to three days), some clinicians administer the drug once per day [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/7\">",
"     7",
"    </a>",
"    ]. For patients with severe renal impairment (creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/minute),",
"    </span>",
"    the dose should be limited to 50 mg twice daily.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     Milnacipran",
"    </a>",
"    can cause several side effects (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"     table 3",
"    </a>",
"    ). A pooled analysis of 1871 patients with major depression who received milnacipran 50 mg two times per day in randomized trials found the following incidence of side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nausea &ndash; 11 percent of patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"       milnacipran",
"      </a>",
"     </li>",
"     <li>",
"      Headache &ndash; 8 percent",
"     </li>",
"     <li>",
"      Dry mouth &ndash; 8 percent",
"     </li>",
"     <li>",
"      Abdominal pain &ndash; 7 percent",
"     </li>",
"     <li>",
"      Constipation &ndash; 7 percent",
"     </li>",
"     <li>",
"      Insomnia &ndash; 6 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Vertigo/dizziness",
"      </span>",
"      &ndash; 5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A study of more than 4000 depressed patients found that tolerability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    was better at 50 mg twice daily than 100 mg twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/36\">",
"     36",
"    </a>",
"    ]. Among patients followed for up to 12 months, most side effects emerged within the first 3 months. &nbsp;",
"   </p>",
"   <p>",
"    Blood pressure may increase in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    and should thus be checked at baseline and regularly thereafter (eg, every two to six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/10\">",
"     10",
"    </a>",
"    ]. Although data from more than 4000 depressed patients treated with milnacipran indicated that the average blood pressure increase was less than 1 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/36\">",
"     36",
"    </a>",
"    ], more recent randomized trials (4567 patients with fibromyalgia randomly assigned to milnacipran or placebo) showed that milnacipran increased both systolic and diastolic pressure by 3 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/12\">",
"     12",
"    </a>",
"    ]. Among fibromyalgia patients with baseline hypertension, the average increase in systolic pressure was more than 15 mmHg greater with milnacipran than placebo. &nbsp;",
"   </p>",
"   <p>",
"    Although abrupt discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    50 mg twice daily after 24 weeks of treatment for major depression does not appear to cause a discontinuation syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/37\">",
"     37",
"    </a>",
"    ], we suggest tapering the drug over one to two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276509267\">",
"    <span class=\"h1\">",
"     VENLAFAXINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although an immediate release formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    is available, the once-daily extended release formulation is commonly used because of ease of administration. Plasma concentrations of the two formulations appear to be comparable at equivalent doses. As an example, 37.5 mg twice daily of the immediate release formulation results in approximately the same plasma concentration as 75 mg daily of the extended-release formulation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with major depression, we typically start",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    extended release with a single morning dose of 37.5 mg. If this is well tolerated, the dose is increased within four to seven days to 75 mg once daily. For patients unresponsive after two to four weeks, the dose is increased by increments of 75 mg per day every two to four weeks, to a recommended maximum of 225 mg once daily. The dose titration can be accelerated, with increases occurring as quickly as every four days (eg, during inpatient treatment). Although the maximum recommended dose of immediate release venlafaxine is 375 mg daily, there is limited experience with extended-release venlafaxine at doses above 225 mg daily. For patients with hepatic impairment, severe renal impairment (creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/minute),",
"    </span>",
"    or end-stage renal disease, the dose is increased by increments of 37.5 mg per day, to a maximum of 112.5 to 150 mg once daily. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    <br/>",
"    The immediate release form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    is typically started at 37.5 mg twice daily. For patients unresponsive after two to four weeks, the dose is increased by 37.5 mg twice daily every two to four weeks, to a recommended maximum of 375 mg per day, in two to three divided doses. For severely depressed patients, the dose can be increased further to 450 mg per day in three divided doses. In clinically urgent situations, the dose is increased by increments of 37.5 mg twice daily every four days. For patients with hepatic impairment, severe renal impairment, or end-stage renal disease, the starting dose is 37.5 mg once daily, and the dose is increased by increments of 37.5 mg per day, to a maximum of 187.5 mg per day, given in two divided doses. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Polymorphism in the hepatic cytochrome P450 enzyme CYP2D6, which converts",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    to the active metabolite",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"     desvenlafaxine",
"    </a>",
"    , may possibly influence the efficacy of venlafaxine. A pooled analysis of four randomized trials compared the efficacy of venlafaxine in 464 patients with unipolar major depression who all received the drug and were classified as extensive or poor metabolizers based upon the plasma concentration ratio of desvenlafaxine to venlafaxine [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/39\">",
"     39",
"    </a>",
"    ]. Remission was greater in patients who were extensive metabolizers compared with poor metabolizers (56 versus 37 percent); the venlafaxine dose and tolerability were comparable for the two groups. However, it is not known whether the effectiveness of venlafaxine is diminished by medications that inhibit CYP2D6. Desvenlafaxine and drug-drug interactions involving SNRIs are discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Desvenlafaxine'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H276509825\">",
"     'Drug-drug interactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     Venlafaxine",
"    </a>",
"    can cause several side effects (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"     table 3",
"    </a>",
"    ), which were examined in a pooled analysis of eight randomized trials that compared venlafaxine with placebo for six or eight weeks in 1348 patients with unipolar major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/40\">",
"     40",
"    </a>",
"    ]. (Venlafaxine was administered as either the extended release formulation 75 to 225 mg per day or the immediate release formulation 75 to 375 mg per day.) Discontinuation due to adverse effects occurred in more patients who received venlafaxine than placebo (9 versus 2 percent). The frequency of side effects in patients treated with venlafaxine compared with placebo was as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nausea &ndash; 24 versus 16 percent",
"     </li>",
"     <li>",
"      Dizziness &ndash; 13 versus 9 percent",
"     </li>",
"     <li>",
"      Dry mouth &ndash; 12 versus 10 percent",
"     </li>",
"     <li>",
"      Insomnia &ndash; 11 versus 11 percent",
"     </li>",
"     <li>",
"      Diaphoresis &ndash; 10 versus 5 percent",
"     </li>",
"     <li>",
"      Constipation &ndash; 9 versus 9 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     Venlafaxine",
"    </a>",
"    may increase the risk of upper gastrointestinal bleeding, but the absolute risk appears to be small [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/41\">",
"     41",
"    </a>",
"    ]. A nested case control study found that use of venlafaxine was nearly three times greater in 1321 patients with upper gastrointestinal tract bleeding, compared to 10,000 controls with no bleeding (odds ratio 2.9, 95% CI 1.5-5.6); use of venlafaxine occurred in 1.1 percent of the cases. The risk of bleeding may be elevated by concomitant use of nonsteroidal anti-inflammatory drugs, particularly among patients not using acid-suppressing agents. &nbsp;",
"   </p>",
"   <p>",
"    Another adverse affect that can occur with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    is increased blood pressure, especially at higher doses.",
"   </p>",
"   <p>",
"    In a meta-analysis of 27 randomized trials that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    with placebo for six weeks in 3424 patients with major depression, the mean increase in supine diastolic blood pressure with venlafaxine was 1 mmHg, which was statistically significant but clinically small, compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/42\">",
"     42",
"    </a>",
"    ]. However, the incidence of supine diastolic blood pressure &ge;90 mmHg (elevated blood pressure) was greater in patients who received venlafaxine than placebo (11 versus 6 percent). In addition, elevated blood pressure occurred in more patients who received venlafaxine at doses &gt;300 mg per day, compared with placebo (9 and 2 percent); by contrast, the frequency of elevated blood pressure was comparable for venlafaxine &le;300 mg per day and placebo (3 and 2 percent of patients). Thus, blood pressure should be checked at baseline, and regularly monitored in patients receiving venlafaxine at doses exceeding 300 mg per day (eg, every two to six months).",
"   </p>",
"   <p>",
"    In addition, meta-analyses suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    impairs sexual function [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/43\">",
"     43",
"    </a>",
"    ], but is weight neutral [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overdoses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    can lead to hypertension, hypotension, cardiac arrhythmias, seizures, the serotonin syndrome, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/7,45,46\">",
"     7,45,46",
"    </a>",
"    ]. Studies of toxicity and death related to venlafaxine have found that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 51 patients who intentionally overdosed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      (mean quantity approximately 1100 mg), the serotonin syndrome occurred in 29 percent and seizures in 14 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Among 235 patients who overdosed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      (median dose 1500 mg), tachycardia occurred in 40 percent, hypertension 28 percent, corrected QT &gt;450 milliseconds in 10 percent, and arrhythmia in 1 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In two studies, the number of deaths caused by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      overdose per one million prescriptions from 1993 to 1999 [",
"      <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/49\">",
"       49",
"      </a>",
"      ] and from 1998 to 2000 [",
"      <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/50\">",
"       50",
"      </a>",
"      ] was greater than that for selective serotonin reuptake inhibitors (SSRIs). However, patients at risk for suicide seem to be more likely to receive venlafaxine than SSRIs [",
"      <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/7,51,52\">",
"       7,51,52",
"      </a>",
"      ]. When the risk of suicide is adjusted for risk factors (eg, prior suicide attempts), the rate of suicide is comparable for patients who receive venlafaxine and SSRIs [",
"      <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who discontinue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    , we suggest tapering the dose by 37.5 to 75 mg per day each week to reduce the incidence of discontinuation emergent adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/10\">",
"     10",
"    </a>",
"    ]. A review found that stopping the drug abruptly can lead to withdrawal symptoms such as anxiety, dizziness, headache, insomnia, nausea, and weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?5/28/5578/abstract/45\">",
"     45",
"    </a>",
"    ]. The discontinuation syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link&amp;anchor=H12#H12\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\", section on 'Discontinuation of antidepressants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"       \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"       \"Patient information: Depression in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The National Institute of Mental Health also has educational material on the use of antidepressants, including serotonin-norepinephrine reuptake inhibitors, entitled, \"What medications are used to treat depression?\" that is available online at the website",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/mental-health-medications/what-medications-are-used-to-treat-depression.shtml\">",
"     file://www.nimh.nih.gov/health/publications/mental-health-medications/what-medications-are-used-to-treat-depression.shtml",
"    </a>",
"    . Material explaining the symptoms, causes, and treatment for depression is also available in a booklet entitled \"Depression\" that is available online at the website",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/depression/index.shtml\">",
"     file://www.nimh.nih.gov/health/publications/depression/index.shtml",
"    </a>",
"    . Both publications can also be obtained through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.",
"   </p>",
"   <p>",
"    The Depression and Bipolar Support Alliance (",
"    <a class=\"external\" href=\"file://www.dbsalliance.org/\">",
"     file://www.dbsalliance.org",
"    </a>",
"    &nbsp;or 800-826-3632) is a national organization whose mission is to educate members about depression and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.",
"   </p>",
"   <p>",
"    The National Alliance on Mental Illness (",
"    <a class=\"external\" href=\"file://www.nami.org/\">",
"     file://www.nami.org",
"    </a>",
"    &nbsp;or 800-950-6264) is a similarly structured organization devoted to providing education, support, and advocacy for patients with any mental illness. Depression is one of their priorities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2257898\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs) include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"       desvenlafaxine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"       milnacipran",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      . SNRIs can be used for the initial treatment of major depression, treatment resistant depression, and other disorders. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      SNRIs appear to treat depression by initially blocking presynaptic serotonin transporter proteins and norepinephrine transporter proteins. This inhibits reuptake of these neurotransmitters and leads to increased stimulation of post-synaptic receptors. SNRIs have little or no effect upon dopaminergic, cholinergic, histaminergic, or alpha1-adrenergic receptors. (See",
"      <a class=\"local\" href=\"#H2257250\">",
"       'Pharmacodynamics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pharmacokinetic parameters of SNRIs vary (",
"      <a class=\"graphic graphic_table graphicRef88063 \" href=\"UTD.htm?14/7/14461\">",
"       table 1",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       Duloxetine",
"      </a>",
"      moderately inhibits the hepatic enzyme CYP2D6. (See",
"      <a class=\"local\" href=\"#H276509802\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to prescribing SNRIs, clinicians should discuss drug interactions, side effects (",
"      <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"       table 3",
"      </a>",
"      ), time to response, and stopping the medication. No specific medical tests are required before starting SNRIs and drug serum concentrations are not routinely performed. Administering SNRIs with food may reduce nausea, which is the most common side effect. (See",
"      <a class=\"local\" href=\"#H276509607\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest starting with the lowest minimal effective dose in order to avoid side effects and slowly increasing the dose in unresponsive patients. Starting doses and target dose ranges of each SNRI are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef88068 \" href=\"UTD.htm?30/41/31388\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H276509636\">",
"       'Dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/33/18967?source=see_link\">",
"       desvenlafaxine",
"      </a>",
"      50 mg per day include nausea, dizziness, sweating, constipation, and anorexia. In addition, blood pressure may increase and should thus be checked at baseline and regularly thereafter (eg, every two to six months). Discontinuation of desvenlafaxine 50 mg per day may cause symptoms, but the discontinuation syndrome is rare. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Desvenlafaxine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       Duloxetine",
"      </a>",
"      is contraindicated in patients with uncontrolled angle-closure (narrow angle) glaucoma; is generally avoided in patients with severe renal impairment (creatinine clearance &lt;30",
"      <span class=\"nowrap\">",
"       mL/minute),",
"      </span>",
"      end-stage renal disease, or hepatic impairment; and should be used cautiously in patients with chronic liver disease or alcohol abuse. Adverse effects include nausea, dry mouth, constipation, insomnia, dizziness, fatigue, diarrhea, somnolence, diaphoresis, decreased appetite, and sexual dysfunction. For patients who discontinue duloxetine, tapering the dose over two to four weeks may reduce discontinuation emergent adverse events such as dizziness, nausea, and headache. (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Duloxetine'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"       Milnacipran",
"      </a>",
"      is contraindicated in patients with uncontrolled angle-closure (narrow angle) glaucoma, generally avoided in patients with end-stage renal disease, and should be used cautiously in patients with chronic liver disease or alcohol abuse due to reports of increased liver enzymes and hepatic injury. Adverse effects include nausea, dizziness, diaphoresis, anxiety, and dysuria. Blood pressure may increase in patients treated with milnacipran and should thus be checked at baseline and regularly thereafter (eg, every two to six months). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Milnacipran'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      include nausea, dizziness, and diaphoresis. Blood pressure may increase and should be checked at baseline; regular monitoring is indicated in patients receiving venlafaxine at doses exceeding 300 mg per day (eg, every two to six months). Sexual dysfunction may occur, and venlafaxine may increase the risk of upper gastrointestinal bleeding. Overdose can cause hypertension, hypotension, cardiac arrhythmias, seizures, the serotonin syndrome, and death. (See",
"      <a class=\"local\" href=\"#H276509267\">",
"       'Venlafaxine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/1\">",
"      Spina E, Trifir&ograve; G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs 2012; 26:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/2\">",
"      Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 1998; 51:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/3\">",
"      Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354:1231.",
"     </a>",
"    </li>",
"    <li>",
"     Thase ME, Sloan DM. Venlafaxine and desvenlafaxine. In: The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, Schatzberg AF, Nemeroff CB.  (Eds), American Psychiatric Publishing, Washington, D.C. 2009. p.439.",
"    </li>",
"    <li>",
"     DrugBank file://www.drugbank.ca (Accessed on July 20, 2012).",
"    </li>",
"    <li>",
"     Norris S, Blier P. Duloxetine and milnacipran. In: The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, Schatzberg AF, Nemeroff CB.  (Eds), American Psychiatric Publishing, Inc., Washington, D.C. 2009. p.453.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/7\">",
"      Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005; 10:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/8\">",
"      Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006; 318:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/9\">",
"      Vaishnavi SN, Nemeroff CB, Plott SJ, et al. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004; 55:320.",
"     </a>",
"    </li>",
"    <li>",
"     Labbate LA, Fava M, Rosenbaum JF, Arana GW. Drugs for the treatment of depression. In: Handbook of Psychiatric Drug Therapy, Sixth Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2010. p.54.",
"    </li>",
"    <li>",
"     Stahl SM. Essential psychopharmacology, 3rd ed, Cambridge University Press, New York 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/12\">",
"      Kyle JA, Dugan BD, Testerman KK. Milnacipran for treatment of fibromyalgia. Ann Pharmacother 2010; 44:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/13\">",
"      Frampton JE, Plosker GL. Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs 2007; 21:581.",
"     </a>",
"    </li>",
"    <li>",
"     Wynn GH, Sandson N, Muniz J. Psychiatry. In: Clinical Manual of Drug Interaction Principles for Medical Practice, Wynn GH, Oesterheld JR, Cozza KL, Armstrong SC.  (Eds), American Psychiatric Publishing, Inc., Washington, DC 2009. p.423.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/15\">",
"      Nakagawa A, Watanabe N, Omori IM, et al. Milnacipran versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009; :CD006529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/16\">",
"      Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/17\">",
"      Desvenlafaxine for depression. Med Lett Drugs Ther 2008; 50:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/18\">",
"      Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002; 63:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/19\">",
"      Lieberman DZ, Massey SH. Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy. Core Evid 2010; 4:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/20\">",
"      Liebowitz MR, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008; 24:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/21\">",
"      DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007; 68:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/22\">",
"      Thase ME, Kornstein SG, Germain JM, et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr 2009; 14:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/23\">",
"      Yang LP, Plosker GL. Desvenlafaxine extended release. CNS Drugs 2008; 22:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/24\">",
"      Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 2007; 68:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/25\">",
"      Montgomery SA, Fava M, Padmanabhan SK, et al. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psychopharmacol 2009; 24:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/26\">",
"      H&auml;user W, Wolfe F, T&ouml;lle T, et al. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs 2012; 26:297.",
"     </a>",
"    </li>",
"    <li>",
"     Prescribing information for duloxetine (Cymbalta) file://pi.lilly.com/us/cymbalta-pi.pdf (Accessed on July 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/28\">",
"      Brecht S, Desaiah D, Marechal ES, et al. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial. J Clin Psychiatry 2011; 72:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/29\">",
"      Waldschmitt C, Vogel F, Pfuhlmann B, Hiemke C. Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey. Pharmacopsychiatry 2009; 42:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/30\">",
"      Hudson JI, Wohlreich MM, Kajdasz DK, et al. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005; 20:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/31\">",
"      Gahimer J, Wernicke J, Yalcin I, et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 2007; 23:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/32\">",
"      Perahia DG, Kajdasz DK, Desaiah D, Haddad PM. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord 2005; 89:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/33\">",
"      Duloxetine (Cymbalta): a new SNRI for depression. Med Lett Drugs Ther 2004; 46:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/34\">",
"      Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev 2009; :CD007115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/35\">",
"      Lopez-Ibor J, Guelfi JD, Pletan Y, et al. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 1996; 11 Suppl 4:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/36\">",
"      Puech A, Montgomery SA, Prost JF, et al. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 1997; 12:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/37\">",
"      Vandel P, Sechter D, Weiller E, et al. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine. Hum Psychopharmacol 2004; 19:585.",
"     </a>",
"    </li>",
"    <li>",
"     Effexor XR (venlafaxine extended release). FDA approved product information. US National Library of Medicine. file://dailymed.nlm.nih.gov/dailymed/about.cfm (Accessed on January 22, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/39\">",
"      Lobello KW, Preskorn SH, Guico-Pabia CJ, et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry 2010; 71:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/40\">",
"      Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 2002; 52:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/41\">",
"      de Abajo FJ, Garc&iacute;a-Rodr&iacute;guez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/42\">",
"      Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/43\">",
"      Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009; 29:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/44\">",
"      Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/45\">",
"      Wellington K, Perry CM. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs 2001; 15:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/46\">",
"      Kelly CA, Dhaun N, Laing WJ, et al. Comparative toxicity of citalopram and the newer antidepressants after overdose. J Toxicol Clin Toxicol 2004; 42:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/47\">",
"      Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 2003; 96:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/48\">",
"      Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol 2007; 64:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/49\">",
"      Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 2002; 325:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/50\">",
"      Cheeta S, Schifano F, Oyefeso A, et al. Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000. Br J Psychiatry 2004; 184:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/51\">",
"      Mines D, Hill D, Yu H, Novelli L. Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol Drug Saf 2005; 14:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/28/5578/abstract/52\">",
"      Rubino A, Roskell N, Tennis P, et al. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 2007; 334:242.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1713 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.97.94.19-BA627EFD15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_28_5578=[""].join("\n");
var outline_f5_28_5578=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2257898\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2256741\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87088683\">",
"      Structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2257250\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H276509802\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H276509825\">",
"      - Drug-drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H276509607\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H276509615\">",
"      Guidelines to review with patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H276509622\">",
"      Medical tests and plasma levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H276509636\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85891991\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18324389\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85891871\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85892292\">",
"      Suicide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DESVENLAFAXINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DULOXETINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MILNACIPRAN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H276509267\">",
"      VENLAFAXINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2257898\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/1713\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1713|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/7/14461\" title=\"table 1\">",
"      SNRI antidepressants - Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/19/43324\" title=\"table 2\">",
"      Serotonin syndrome drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/46/38639\" title=\"table 3\">",
"      Side effects antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/41/31388\" title=\"table 4\">",
"      SNRIs - Doses for treating unipolar depression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=related_link\">",
"      Antidepressant medication in adults: Switching and discontinuing medication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5417?source=related_link\">",
"      Atypical antidepressants: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=related_link\">",
"      Depression in pregnant women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43783?source=related_link\">",
"      Effect of antidepressants on suicide risk in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7574?source=related_link\">",
"      Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=related_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5129?source=related_link\">",
"      Serotonin modulators: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/39/9850?source=related_link\">",
"      Unipolar depression in adults: Continuation and maintenance treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_28_5579="Changes in last hours of life";
var content_f5_28_5579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Checklist for discussions with family about the last hours of life",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Progressive unresponsiveness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Purposeless movements, facial expressions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Noisy breathing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unlikely periods of awareness just before death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Possible acute events and action plan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any other questions the family may have",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ask about previous deaths in the family (where, when, how)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phone number (24 hours) for help",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What to do after death",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_28_5579=[""].join("\n");
var outline_f5_28_5579=null;
var title_f5_28_5580="Radiation tox cutaneous";
var content_f5_28_5580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Radiation toxicity: cutaneous system",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptom/sign",
"       </td>",
"       <td class=\"subtitle1\">",
"        Degree1",
"       </td>",
"       <td class=\"subtitle1\">",
"        Degree 2",
"       </td>",
"       <td class=\"subtitle1\">",
"        Degree 3",
"       </td>",
"       <td class=\"subtitle1\">",
"        Degree 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema",
"       </td>",
"       <td>",
"        Minimal, transient",
"       </td>",
"       <td>",
"        Moderate &lt;10 percent BSA",
"       </td>",
"       <td>",
"        Marked 10-40 percent BSA",
"       </td>",
"       <td>",
"        Severe &gt;40 percent BSA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sensation/itching",
"       </td>",
"       <td>",
"        Pruritus",
"       </td>",
"       <td>",
"        Slight, int. pain",
"       </td>",
"       <td>",
"        Moderate persistent pain",
"       </td>",
"       <td>",
"        Severe persistent pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blistering",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Rare hemorrhage",
"       </td>",
"       <td>",
"        Bullae",
"       </td>",
"       <td>",
"        Bullae hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desquamation",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Patchy, dry",
"       </td>",
"       <td>",
"        Patchy, moist",
"       </td>",
"       <td>",
"        Confluent, moist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcer/necrosis",
"       </td>",
"       <td>",
"        Epidermal only",
"       </td>",
"       <td>",
"        Dermal",
"       </td>",
"       <td>",
"        Subcutaneous",
"       </td>",
"       <td>",
"        Muscle or bone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Onycholysis",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Partial",
"       </td>",
"       <td>",
"        Partial",
"       </td>",
"       <td>",
"        Complete",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BSA: body surface area; Int: intermittent.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Waselenko, JK, MacVittie, TJ, Blakely, WF, et al. Medical management of the acute radiation syndrome: Recommendations of the strategic national stockpile radiation working group. Ann Int Med 2004; 140:1039. Copyright &copy;2004 American College of Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_28_5580=[""].join("\n");
var outline_f5_28_5580=null;
var title_f5_28_5581="Causes systolic ejection murmur";
var content_f5_28_5581=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bedside diagnosis of the principal causes of systolic ejection murmur in adult patients (flow and innocent murmurs)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Identification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A systolic ejection murmur (SEM) begins after S1, terminates",
"before A2 and/or P2-A2, is clearly heard over the cardiac apex, and is",
"usually crescendo-decrescendo configuration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Useful maneuvers to differentiate from regurgitant murmur:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hand grip usually decreases the intensity of the ejection murmur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Amyl nitrite usually increases the intensity of the ejection murmur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Normal Carotid Pulse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Increased flow across the aortic valve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Aortic regurgitation: aortic diastolic murmur and other features of aortic regurgitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypermetabolic state: hyperdynamic cardiac impulse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aortic sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Elderly patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Short and soft SEM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Normal S1 and S2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Normal cardiac impulse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        \"Grunting\" quality of the murmur may be present.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Suspected uncomplicated bicuspid aortic valve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Short and soft SEM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Normal S1 and S2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Aortic ejection sound in the absence of aortic aneurysm, hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Short, early aortic diastolic murmur may be present.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Normal cardiac impulse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suspected atrial septal defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Short and soft SEM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Wide and fixed splitting of S2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Wide splitting of S1; tricuspid opening snap; mid-diastolic rumble over the lower left sternal border may be present.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hyperdynamic left parasternal impulse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Suspected idiopathic dilatation of the pulmonary artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Short and soft SEM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        S1 normal; S2 may be widely split; normal inspiratory increase in A2-P2 interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pulmonary ejection sound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Short, early pulmonary diastolic murmur may be present.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Normal cardiac impulse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Innocent murmur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Short and soft SEM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Normal S1 and S2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Normal cardiac impulse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        No evidence for any hemodynamic abnormality",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_28_5581=[""].join("\n");
var outline_f5_28_5581=null;
var title_f5_28_5582="Survival rates for extremely premature infants";
var content_f5_28_5582=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected studies reporting survival for infants 22 to 25 weeks gestation during the initial NICU admission",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"10%\">",
"     </colgroup>",
"     <colgroup span=\"5\" width=\"14%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Region/country",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Study years",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Survival [n/N (percent)] by gestational age (week)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        22",
"       </td>",
"       <td class=\"subtitle2\">",
"        23",
"       </td>",
"       <td class=\"subtitle2\">",
"        24",
"       </td>",
"       <td class=\"subtitle2\">",
"        25",
"       </td>",
"       <td class=\"subtitle2\">",
"        Total",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EPICure*",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        UK; Ireland",
"       </td>",
"       <td>",
"        1995",
"       </td>",
"       <td>",
"        2/22 (9)",
"       </td>",
"       <td>",
"        26/131 (20)",
"       </td>",
"       <td>",
"        100/298 (34)",
"       </td>",
"       <td>",
"        186/357 (52)",
"       </td>",
"       <td>",
"        314/811 (39)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epipage*",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        9 regions in France",
"       </td>",
"       <td>",
"        1997",
"       </td>",
"       <td>",
"        0/16 (0)",
"       </td>",
"       <td>",
"        0/30 (0)",
"       </td>",
"       <td>",
"        13/42 (31)",
"       </td>",
"       <td>",
"        59/119 (50)",
"       </td>",
"       <td>",
"        72/207 (35)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Trent regional study",
"        <sup>",
"         [3,4]",
"        </sup>",
"       </td>",
"       <td rowspan=\"3\">",
"        Trent, UK",
"       </td>",
"       <td>",
"        1994-1999",
"       </td>",
"       <td>",
"        0/15 (0)",
"       </td>",
"       <td>",
"        15/81 (19)",
"       </td>",
"       <td>",
"        40/165 (24)",
"       </td>",
"       <td>",
"        119/229 (52)",
"       </td>",
"       <td>",
"        174/490 (36)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2000-2005",
"       </td>",
"       <td>",
"        0/9 (0)",
"       </td>",
"       <td>",
"        12/65 (18)",
"       </td>",
"       <td>",
"        82/198 (41)",
"       </td>",
"       <td>",
"        142/229 (63)",
"       </td>",
"       <td>",
"        236/497 (47)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2006-2010",
"       </td>",
"       <td>",
"        0/1 (0)",
"       </td>",
"       <td>",
"        16/80 (20)",
"       </td>",
"       <td>",
"        66/151 (44)",
"       </td>",
"       <td>",
"        137/204 (67)",
"       </td>",
"       <td>",
"        219/436 (50)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Markestad*",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        Norway",
"       </td>",
"       <td>",
"        1999",
"       </td>",
"       <td>",
"        0/2 (0)",
"       </td>",
"       <td>",
"        9/23 (39)",
"       </td>",
"       <td>",
"        35/68 (60)",
"       </td>",
"       <td>",
"        55/69 (80)",
"       </td>",
"       <td>",
"        99/152 (65)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tyson",
"        <sup>",
"         &bull;[6]",
"        </sup>",
"       </td>",
"       <td>",
"        19 NRN sites, USA",
"       </td>",
"       <td>",
"        1998-2003",
"       </td>",
"       <td>",
"        (5)",
"       </td>",
"       <td>",
"        (26)",
"       </td>",
"       <td>",
"        (56)",
"       </td>",
"       <td>",
"        (75)",
"       </td>",
"       <td>",
"        2267/4446 (51)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Carlo",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td rowspan=\"3\">",
"        23 NRN sites, USA",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"6\">",
"        1993-2009",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ANS",
"       </td>",
"       <td>",
"        32/118 (27)",
"       </td>",
"       <td>",
"        480/1147 (42)",
"       </td>",
"       <td>",
"        1799/2976 (60)",
"       </td>",
"       <td>",
"        2721/3555 (77)",
"       </td>",
"       <td>",
"        5032/7796 (64)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No ANS",
"       </td>",
"       <td>",
"        50/283 (18)",
"       </td>",
"       <td>",
"        225/831 (27)",
"       </td>",
"       <td>",
"        399/814 (49)",
"       </td>",
"       <td>",
"        528/804 (66)",
"       </td>",
"       <td>",
"        1202/2732 (44)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itabashi*",
"        <sup>",
"         [8]",
"        </sup>",
"       </td>",
"       <td>",
"        Japan",
"       </td>",
"       <td>",
"        2005",
"       </td>",
"       <td>",
"        33/97 (34)",
"       </td>",
"       <td>",
"        153/282 (54)",
"       </td>",
"       <td>",
"        324/423 (77)",
"       </td>",
"       <td>",
"        428/501 (85)",
"       </td>",
"       <td>",
"        938/1303 (72)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EXPRESS",
"        <sup>",
"         &Delta;[9]",
"        </sup>",
"       </td>",
"       <td>",
"        Sweden",
"       </td>",
"       <td>",
"        2004-2007",
"       </td>",
"       <td>",
"        5/51 (10)",
"       </td>",
"       <td>",
"        53/101 (53)",
"       </td>",
"       <td>",
"        96/144 (67)",
"       </td>",
"       <td>",
"        167/205 (81)",
"       </td>",
"       <td>",
"        321/501 (64)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stoll*",
"        <sup>",
"         [10]",
"        </sup>",
"       </td>",
"       <td>",
"        20 NRN sites, USA",
"       </td>",
"       <td>",
"        2003-2007",
"       </td>",
"       <td>",
"        25/421 (6)",
"       </td>",
"       <td>",
"        226/871 (26)",
"       </td>",
"       <td>",
"        754/1370 (55)",
"       </td>",
"       <td>",
"        1079/1498 (72)",
"       </td>",
"       <td>",
"        2084/4160 (50)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NICU: Neonatal Intensive Care Unit; UK: United Kingdom; NRN: Neonatal Research Network; ANS: antenatal steroid therapy.",
"     <br/>",
"     * Survival of NICU admissions to discharge.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Survival of NICU admissions until 18 to 22 months corrected age.",
"     <br/>",
"     &Delta; Survival of NICU admissions to 1 year.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Costeloe K, Hennessy E, Gibson AT, et al. The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability. Pediatrics 2000; 106:659.",
"      </li>",
"      <li>",
"       Larroque B, Br&eacute;art G, Kaminski M, et al. Survival of very preterm infants: Epipage, a population based cohort study. Arch Dis Child Fetal Neonatal Ed 2004; 89:F139.",
"      </li>",
"      <li>",
"       Field DJ, Dorling JS, Manktelow BN, Draper ES. Survival of extremely premature babies in a geographically defined population: prospective cohort study of 1994-9 compared with 2000-5. BMJ 2008; 336:1221.",
"      </li>",
"      <li>",
"       Seaton SE, King S, Manktelow BN, et al. Arch Dis Child Fetal Neontal Ed 2013; 98:F15.",
"      </li>",
"      <li>",
"       Markestad T, Kaaresen PI, R&oslash;nnestad A, et al. Early death, morbidity, and need of treatment among extremely premature infants. Pediatrics 2005; 115:1289.",
"      </li>",
"      <li>",
"       Tyson JE, Parikh NA, Langer J, et al. Intensive care for extreme prematurity--moving beyond gestational age. N Engl J Med 2008; 358:1672.",
"      </li>",
"      <li>",
"       Carlo WA, McDonald SA, Fanaroff AA, et al. Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks' gestation. JAMA 2011; 306:2348.",
"      </li>",
"      <li>",
"       Itabashi K, Horiuchi T, Kusuda S, et al. Mortality rates for extremely low birth weight infants born in Japan in 2005. Pediatrics 2009; 123:445.",
"      </li>",
"      <li>",
"       EXPRESS Group, Fellman V, Hellstr&ouml;m-Westas L, et al. One-year survival of extremely preterm infants after active perinatal care in Sweden. JAMA 2009; 301:2225.",
"      </li>",
"      <li>",
"       Stoll BJ, Hansen NI, Bell EF, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010; 126:443.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_28_5582=[""].join("\n");
var outline_f5_28_5582=null;
var title_f5_28_5583="90 90 rest position";
var content_f5_28_5583=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    90/90 rest position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 188px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 90/90 rest position for patients with low back pain is achieved by lying on a flat surface and flexing both hips and knees to 90 degrees.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     By permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_28_5583=[""].join("\n");
var outline_f5_28_5583=null;
